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INTRODUCTION 
The goal of this study was to determine the applicability 
of a technique, signature analysis, for examining the 
serological relationships among serotypes of a plant virus. 
Cowpea severe mosaic virus (CPSMV) was used as a model system 
for this study. Signature analysis is a relatively new 
serological approach which employs radioimmunoassay and 
monoclonal antibodies (MAbs) to examine the subtle antigenic 
differences among isolates of viruses. It has only been used 
to study animal viruses, e.g., hepatitis B virus (Wands et 
al., 1984) and dengue-2 virus (Monath et al., 1986). With 
this approach, far more antigenic heterogeneity has been 
demonstrated in thses two viruses than previously shown by 
polyclonal antibodies. 
CPSMV, a comovirus, includes nine serotypes (I to IX) 
determined by immunodiffusion tests with polyclonal antibodies 
(Lin et al., 1981, 1984, and Lin, personal communication, 
Bioplanta Tecnologia de Plantas s. A., Brazil). Several 
common or specific antigenic determinants have been 
identified. This makes CPSMV an ideal model to study whether 
signature analysis can be used to reveal the subtle antigenic 
differences among serotypes of a plant virus. 
The theory of MAb was first developed in the late 1950s 
and achieved practical application in the late 1970s. 
Presently, MAbs are widely used in both animal and plant 
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sciences. For the purpose of this study, the most significant 
properties of MAbs are their greater specificity and 
homogeneity as compared to polyclonal antibodies. MAbs were 
made to CPSMV I, II and III. They were characterized by 
simultaneous and consecutive competition ELISAs (enzyme-linked 
immunosorbent assays) for their binding characteristics to 
serotypes of CPSMV. 
Seven MAbs were selected to form a panel for use in 
biotin-avidin-based signature analysis assays to study the 
serological relationships among nine serotypes of CPSMV. With 
this study, signature analysis has been proven to be able to 
identify antigenic divergence among isolates of plant viruses. 
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LITERATURE REVIEW 
Cowpea Severe Mosaic Virus 
Cowpea severe mosaic virus (CPSMV, Rjl:*j*:SjS:SjC, 
Ve/Cl) belongs to the comovirus group (de Jager, 1979). 
CPSMV, a multicomponent virus, consists of three icosahedral 
particles with a diameter of approximately 25 nm which can be 
separated into three centrifugal components: top (T), 
consisting of empty protein shells; and two nucleoproteins, 
middle (M) and bottom (B) . The M and B particles are 
morphologically and serologically identical but contain RNA 
molecules of different molecular weight (Shepherd, 1964; 
Thongmeearkom and Goodman, 1978). 
According to the original CMI/AAB (Commonwealth 
Mycological Institute of Association of Applied Biology) 
description of cowpea mosaic virus (CPMV), all isolates of 
CPMV could be separated into severe and yellow subgroups based 
on serological and host reactions (van Kammen, 1971). Later, 
Swaans and van Kammen (1973), after a thorough study of host 
range, symptomatology and the ratio of virus components of the 
two subgroups, concluded that they should be considered as two 
different viruses. For example, the symptoms of both 
subgroups differ markedly on most species tested; each isolate 
possesses a specific antigenic group and there is no homology 
in nucleotide sequence between the RNAs of the two isolates. 
Based upon serological differences, Fulton and Scott (1979) 
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proposed the serogrouping concepts for legume comoviruses and 
considered the severe and yellow subgroups as distinct viruses 
which were designated as the CPMV-Arkansas and CPMV-Sb 
serogroups, respectively. The recent CMI/AAB Description of 
Plant Viruses also considered the severe and yellow subgroups 
as distinct viruses and officially designated them as cowpea 
severe mosaic virus (CPSMV) and cowpea mosaic virus (CPMV), 
respectively (de Jager,1979; van Kammen and de Jager, 1978). 
The studies of Lin et al. (1981) showed that single-
lesion isolates of cowpea severe mosaic virus obtained from 
central Brazil could be differentiated by immunodiffusion 
tests, in agar gel, into two serologically distinct groups; 
namely, serotype I and serotype II. Isolates of serotype I 
infected the soybean (Glycine max) cultivar IAC-2 which was 
immune to serotype II. Two additional serotypes III and IV 
were identified from CPSMV isolates (Lin et al., 1984). Only 
serotype III could infect Nicotiana tabacum "TNN". Serotype 
IV was unable to infect Chenopodium amaranticolor, a known 
diagnostic host for this virus. Two beetle species, Cerotoma 
arcuata and Diabrotica speciosa, could transmit serotype IV 
from beans to beans. Two major proteins with apparent 
molecular weights of 40,300-41,800 daltons and 20,000-21,400 
daltons were detected in the middle components of the four 
serotypes. A minor protein of about 22,400-23,300 daltons was 
detected in serotypes I, III and IV, but not in serotype II. 
Serological comparison, by immunodiffusion tests, showed 
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that the four serotypes had a common antigenic determinant 
designated "A". Serotypes I,III and IV shared an additional 
common determinant designated as "B". Serotypes I and IV had 
the common determinant designated as "C". Each serotype also 
had a specific antigenic determinant designated as "D", 
"E","F" or "G" for serotypes I, II, III and IV, respectively. 
Lin (personal communication, Bioplanta Tecnologia de 
Plantas s. A., Brazia), using the same immunodiffusion tests, 
identified five other serotypes of CPSMV; namely V (CR7), VI 
(S-1}, VII (Ill}, VIII (DG}, and IX (ATCC-PV273). 
CPSMV has several synonyms: Arkansas cowpea virus 
(Shepherd, 1964}, Trinidad cowpea mosaic virus (Chant, 1962} 
and CPMV-severe subgroup (Thongmeearkom and Goodman, 1978}. 
Diseases caused by CPSMV are found in USA, Trinidad, 
Puerto Rico, El Salvador, Costa Rica, Venezuela, Surinam, 
Brazil and Peru (de Jager, 1979). The disease incidence in 
cowpea (Vigna unguiculata) may be up to 100% (Dale, 1949;}. 
Reduction of up to 50% in the number of pods and fresh weight 
was observed in CPSMV infection on cowpea (Debrot and de 
Bojas, 1967). The host range of CPSMV includes many 
leguminous crops and weeds and some solanaceous plants such as 
Phaseolus, Chenopodium amaranticolor and Nicotiana benthamiana 
(Anjos and Lin, 1984; Fribourg and Koenig, 1985). Almost all 
host plants develop necrotic or chlorotic lesions on 
inoculated leaves. Systemic symptoms are mottle or mosaic 
which often includes severe blistering and distortion of 
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leaflets (de Jager, 1979). 
CPSMV is mechanically transmissible (de Jager, 1979). It 
is also transmitted by leaf-feeding beetles. Those of the 
family Chrysomelidae, Cerotoma ruficornis and ~- trifurcata 
are among the most important (de Jager, 1979). A seed 
transmission rate of 8% was reported for the Trinidad isolate 
in asparagus bean (Vigna sesguipedalis) (Dale, 1949). 
Amorphous inclusion bodies were found near or surrounding 
the nucleus in epidermal strips of infected cowpeas and peas 
(Agrawal, 1964: Swaans and van Kammen, 1973). 
Debrot and de Rojas (1967) concluded that virus from the 
primary leaves of Pinto beans infected with CPSMV had a 
thermal inactivation point between 65 and 70 c, a dilution end 
point from 10-4 to 10-5 and a longevity in vitro of one to 
five days at a temperature of 24 c. 
Monoclonal Antibodies 
Immunoassays have been used by scientists working in all 
areas of biology. Antibodies can be generated that are 
specific for substances to be studied, and such antibodies can 
be employed in any of many standard immunoassays. However, 
many scientists are frustrated by the unpredictability of the 
immune response (Scharff, 1984). Some macromolecules are only 
weakly immunogenic, and it may be difficult to obtain high 
titer antisera for their detection. At least 100 ug of 
antigen, in relatively pure form, is required even for 
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substances that can induce an excellent antibody response. If 
impure antigens are used, the antiserum must be extensively 
cross-absorbed with heterologous antigens to achieve strain-
specificity. Even if large amounts of a pure and highly 
immunogenic immunogen are injected, the recipient animal will 
make antibodies that differ widely in affinity and ability to 
induce precipitation, fixation of complement and binding to 
phagocytic cells. Each bleeding must be considered as a 
unique serological reagent and the amount of antibody obtained 
is often inadequate. These, and other problems, have led 
immunologists to seek techniques for producing more homologous 
and reproducible immunoreagents in larger amounts. 
The theory of MAb developed from the hypothesis of clonal 
selection (Burnet, 1959) . It assumes that, in animals, there 
exist clones of mesenchymal cell which carry immunologically 
reactive sites corresponding, in appropriate complementary 
fashion, to one potential antigenic determinant. When an 
antigen is introduced it will make contact with a cell of the 
corresponding clone which is presumably a lymphocyte. By this 
mechanism, production of globulin molecules of the 
characteristic type is stimulated. 
The achievements of: 1) in vitro culture of normal and 
malignant cells, 2) chemically defined culture media, and 3) 
usage of Sendai virus and polyethylene glycol-based fusing 
technology, made the development of hybridoma technology 
possible (Goldsby, Srikumaran and Gui dry, 1984). Cohn (1967) 
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and Potter (1972) found that tumors induced by injecting 
mineral oil into the peritoneal cavity of mice could be passed 
to other mice and a continuous supply of antibodies of a 
single specificity could be achieved. In 1973, Schwaber and 
Cohen used inactivated Sendai virus to fuse human lymphocytes 
from normal donors to a mouse plasmacytoma. They were the 
first to demonstrate that one could immortalize the antibody 
production of a normal cell of the B lymphocyte lineage by 
fusing it in vitro with a plasma cell tumor. 
In 1975, Kohler and Milstein devised and demonstrated a 
strategy for the deliberate and rational construction of 
continuous cell lines that secreted MAb of desired 
specificity. They fused HAT (hypoxanthine, aminopterin and 
thymidine)-selectable mouse myeloma cells with spleen cells 
from mice that had been previously immunized with sheep red 
blood cells. They then screened the resulting hybrids for the 
production of antibody specific for sheep red blood cells. 
MAb can provide several advantages as compared with 
polyclonal antibodies. Ten times less antigen are required 
for immunization. MAbs have greater specificity than 
polyclonal antibody. The molecular homogeneity of a MAb 
ensures that only one antigenic determinant of the antigen is 
analyzed at one time. Therefore, it is possible to 
demonstrate fine distinctions between closly related virus 
strains in a reproducible manner. Additionally, once a useful 
hybridoma has been established, virtually unlimited quantities 
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of a particular MAb can be produced. 
Conversely, MAbs also have disadvantages. Generating 
MAbs is very time-consuming, expensive and it requires a high 
level of expertise. Difficulties may exist in generating MAbs 
against weakly immunogenic molecules. This can also be true 
for generating polyclonal antibodies (Scharff, 1984). The 
very high specificity of MAbs may also be a problem for some 
applications, as they may recognize only the immunizing 
serotype of the antigen and not other prevalent serotypes. In 
addition, Van Regenmortel (1984) reported that some of the 
MoAbs specific to a particular strain of TMV often reacted 
better with other strains. He suggested that 
heterospecificity is more obvious with MAbs than with 
polyclonal antibodies because the heterospecificity is not 
masked by the other antibodies found in an antiserum. The 
selection of MAbs specific for common epitopes of different 
serotypes as well as the judicious mixture of different MAbs 
should make it possible to overcome these difficulties. Diaco 
et al. (1986) reported that some MAb preparations produced 
against barley yellow dwarf virus (BYDV), although of 
equivalent titre, were more reactive with heterologous than 
with homologous isolates of BYDV. This phenomenon has been 
referred as heteroclitic, or heterospecific (Al-Moudallal et 
al., 1982). 
The hybridoma technique has been used extensively in 
medical and veterinary studies. Only since the early 1980s, 
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has it been introduced into the research of plant pathology. 
MAbs specific for more than 20 plant viruses have been 
obtained (Van Regenmortel, 1984). The detection of antigenic 
changes induced by a single amino acid substitution in the 
protein coat of tobacco mosaic virus has been achieved by MAbs 
(Al Moudallal et al., 1982). Hill et al. (1984) demonstrated 
that it was possible to detect soybean mosaic virus, lettuce 
mosaic virus and maize dwarf mosaic virus successfully, using 
a single MAb in competitive radioimmunoassays. Due to the 
unique specificity of MAbs, they have proven to be valuable 
reagents for virus classification and serotyping of viruses 
(Halk et al., 1984). 
Immunoassay 
Various immunoassays have been applied for the detection 
and grouping of plant viruses. For example, immunodiffusion 
tests have provided strong evidence for existence of serotypes 
of CPSMV (Lin et al., 1984). Many of these tests are easy to 
perform, but the results may take days to obtain. 
Immunoelectrophoresis tests have the advantage of being rapid. 
Immunofluorescence is rather subjective and is labor 
intensive; in contrast, radioimmunoassay (RIA) is objective 
and can be automated, but it often utilizes reagents with a 
rather short shelf life (Voller et al., 1980). In addition, 
researchers are subject to exposure to radioactive isotopes. 
Enzyme-immunoassay is also objective and can be automated; it 
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is free from the potential danger of radioactive substances 
and the reagents used have a long shelf life. Only cheap 
simple equipment is required. In addition, since both ELISA 
and RIA are governed by the same thermodynamic constraints, 
and the enzyme can be detected in the same range of molarity 
as commonly used radioisotopes, the sensitivity and 
specificity of RIA and ELISA are comparable (Berzofsky and 
Berkower, 1984). 
For the detection of plant viruses, the "double antibody 
sandwich" form of ELISA has been found to be suitable (Voller 
et al., 1976). In this method, the specific antibody has been 
first adsorbed onto a solid surface to selectively trap and 
immobilize the virus in the test sample. A second enzyme-
linked antibody is allowed to react with the trapped virus. 
This complex of enzyme-labeled antibody with the antigen is 
then detected calorimetrically by adding an appropriate 
suitable enzyme substrate. In general, this system can detect 
viruses at concentrations of 10-100 ngjml (Voller et al., 
1976). However, Clark and Adams (1977) have reported 
detection levels as low as 1 ngjml. 
Variants of ELISA were compared by Koenig and Paul (1982) 
for the detection and differentiation of plant viruses. 
Indirect ELISA on plates not precoated with antibodies was 
found to detect the broadest range of serologically related 
viruses. In this assay, the antigen to be tested is bound 
directly to the solid surface, followed by a specific 
12 
antibody. An enzyme-labelled antiglobulin, reactive with the 
specific antibody is then added. After adding the enzyme 
substrate, the color change is measured 
spectrophotometrically. In this assay, commercially available 
enzyme-labeled antiglobulin can be used. This obviates the 
storage and preparation of many different conjugated 
antibodies. 
Indirect ELISA can also be utilized in the screening 
process to identify hybridomas which produce specific MAb. It 
is a highly sensitive screening test for hybrid cell cultures 
at early stages of their development. In addition, it can be 
rapidly performed on a large number of samples. It also has 
the advantage of being independent of the hybridoma antibody 
isotype (Yewdell and Gerhard, 1981). Media from hybridoma 
cells growing in tissue culture plates are transferred to an 
ELISA plate which has been coated with antigen and blocked 
with a blocking agent. Enzyme-conjugated rabbit or goat anti-
mouse IgG or IgM and enzyme substrate are added, and the 
reaction products are measured spectrophotometrically. In 
this manner, wells in the tissue culture plate which contain 
specific antibody-secreting hybridomas can be identified. 
The biotin-avidin system is another alternative for 
enzyme immunoassays. It was originally described by Bayer and 
Wilchek (1974) for immunochemical staining. Avidin, a 
glycoprotein with a molecular weight of 67,000, has an 
exceptionally high affinity for biotin (dissociation constant: 
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10-15 M) (Green, 1963). It possesses 4 active sites for 
binding biotin. In addition, the biotin-avidin system offers 
several other advantages: (1) both biotin and avidin are 
stable; (2) biotin can be attached to small ligands and 
macromolecules efficiently and under very mild conditions; 
(3) usually, the physical characteristics and biological 
activity of biotin-derivatized proteins are not changed; (4) 
both biotin and avidin are relatively inexpensive (Bayer et 
al. , 1979) . 
Guesdon et al. (1979) introduced the biotin-avidin system 
into enzyme-immunoassays. It was found that the antigen-
binding capacity of antibody was not modified even with 
extensive substitution by biotin for amino groups in antibody 
molecules. Kendall et al. (1983) reported that an ELISA 
procedure involving biotinylated goat anti-mouse gamma 
immunoglobulin (IgG) and avidin-alkaline phosphatase was 4134 
times more sensitive than AUSAB (a commercial 
radioimmunoassay, Abbott Laboratories, North Chicago, IL) for 
the detection of mouse antibody to hepatitis B surface 
antigen. Diaco et al. (1985) used a biotinylated second 
antibody and an avidin-alkaline phosphatase detection system 
in a double-antibody sandwich ELISA to detect soybean mosaic 
virus (SMV) in soybean seed extracts. It was found that this 
system could detect less than 10 ng of SMV/ml, which was more 
sensitive than 25 ngjm1 detected by a po1yc1onal antibody-
based solid-phase radioimmunoassay (SPRIA). Furthermore, the 
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biotin-avidin system required much less time for seed sample 
assays than SPRIA did. 
Topographic Analysis 
The discriminatory power of MAbs makes them an ideal 
reagent for investigation of antigenic relationships between 
viral proteins. They are invaluable for identifying minor 
antigenic differences between closely related proteins. There 
are three types of experiments that can provide insight into 
the antigenic topology of viral proteins (Yewdell and Gerhard, 
1981). The first is to construct an operational antigenic map 
by comparative antigenic analysis of antigenic mutant 
proteins. The second type of experimental approach is to 
study the capacity of antibodies to compete for antigenic 
sites on the viral protein. Results are then correlated with 
the functional and physical antigenic topology of the virus. 
The examination of the structural properties of the epitopes 
themselves is the third type of experiment. 
In an antibody competition study, one MAb carries a 
marker, and unlabeled antibodies are examined for their 
ability to inhibit binding of labeled antibody with antigen. 
The antibody can be labeled with radioisotope or with biotin 
as described previously. If the unlabeled antibody fails to 
reduce the binding of labeled antibody, the two antibodies 
bind to distinct epitopes on the antigen. If antibodies are 
observed to compete for binding to antigen, several 
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explanations are possible. First, the antibodies may 
delineate structurally overlapping epitopes. Second, binding 
of one antibody may prevent access of the second antibody to a 
physically distinct site; in this case the proximity of the 
two epitopes creates steric hindrance between the antibody 
molecules. Third, the binding of some MAbs may induce 
conformational changes in the antigen and thereby alter the 
epitope recognized by the competing antibody. There is also 
another possibility, suggested by Friguet et al. (1983), that 
the antigen oscillates between two conformations; if the first 
antibody species binds exclusively to one conformation while 
the second one binds exclusively to the other, it will be 
impossible for the two antibodies to bind simultaneously to 
the antigen even if they are specific for distinct epitopes. 
Antibody competition assays tend to exaggerate the physical 
proximity between epitopes. Thus, competition assays provide 
the most information when the binding of antibodies to a 
protein can be shown to be noncompetitive. 
Both simultaneous and consecutive (sequential) 
competition assays can be used to characterize competition 
between antibodies (Yewdell and Gerhard, 1981) . In the former 
assay, the unlabeled antibody and the labeled antibody are 
added together. If the binding of the labeled antibody is 
decreased by 50% or more, true competition is likely. If 
binding of the labeled antibody to the epitope is decreased by 
100% in the consecutive competition assay, true competition is 
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likely (Kubanek, 1987). As suggested by Schmaljohn et al. 
(1983), if the unlabeled antibody caused at least a 50% 
inhibition in binding of the labeled antibody, the two 
antibodies were presumed to bind to the same or to the 
topographically related epitopes. 
The antibody competition assays delineate and 
characterize the antigenic topographic map of antigens. 
Breschkin et al. (1981) studied the topography of antigenic 
determinants of influenza virus hemagglutinin by competitive 
RIA. The unlabeled MAb was used to block the binding of 
radiolabeled heterologous MAbs. Pairs of MAbs that competed 
completely were considered as binding in the same antigenic 
region. Other pairs bound non-competitively to physically 
distinct regions. Thus, the existence of four distinct 
antigenic sites was demonstrated. Sindbis virus epitopes were 
grouped into six spatially distinct antigenic sites by 
Schmaljohn et al. (1983). Employing ELISA, the binding of 
individual peroxidase-labeled MAbs to immobilized (solid-
phase), detergent-disrupted Sindbis virus was inhibited 
specifically by one or more unlabeled antibodies . 
These techniques, delineating antigenic topographic maps 
of antigens, have been used in plant virology. The studies by 
Dougherty et al. (1985) indicated that MAbs to tobacco etch 
virus (TEV) capsid protein could be grouped into two classes. 
One group recognized surface epitopes specific for TEV: the 
other one defined internal epitopes which were not unique to 
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TEV. Diaco et al. (1985) demonstrated that there were at 
least two epitopes present on the coat protein of the P-PAV 
isolate of BYDV in a competition ELISA. In this system, one 
MAb was labeled with biotin; its binding to the antigen was 
inhibited by an unlabeled antibody. 
Signature analysis is a relatively new technique which 
has been used in animal virology (Wands et al., 1984; Monath 
et al., 1986). This approach employs radioimmunoassay and a 
small panel of labeled MAbs specific for different epitopes 
(VanDeusen, 1984). When comparing subtypes of the virus, 
differences in the relative occurrence of each epitope as well 
as variations within the epitopes are observed. This method 
avoids the necessity for the knowledge of viral protein 
concentration in complex protein mixtures in order to identify 
differences in antigens. 
In signature analysis, a group-reactive MAb with high 
avidity is used to capture virus onto the solid phase. The 
solid phase is incubated with dilutions of antigen and 
iodinated antibody. The bound radioactivity is counted and 
graphed against the antigen concentration. Thus, the 
"signature" or "fingerprint" of the immunoreactivity between 
antigen and the iodinated antibody is generated. 
Using this approach, Wands et al. (1984) showed that 
hepatitis B (HBs) viral antigen exhibited far more antigenic 
heterogeneity than previously recognized by polyvalent anti-
HBs antibodies; i.e., there were subtypes within the classic 
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HBs antigen subtypes. Also by signature analysis, Monath et 
al. {1986) revealed striking antigenic differences among the 
prototype and four geographic topotype strains of Dengue-2 
virus, and a high degree of antigenic similarity among strains 
from the same geographic region. 
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MATERIALS AND METHODS 
Distilled and Deionized Water 
Distilled and deionized water (ddH20) was used in the 
preparation of all media and buffers. This was obtained by 
passing distilled water through a Super-Q Ultra Pure Water 
System (Millipore Corp., Bedford, MA), which removed both 
organic and inorganic ions. 
Virus Propagation 
Cowpea severe mosaic virus (CPSMV) serotypes I to IX were 
propagated in and purified from Vigna unguiculata Walp. 
(California blackeye cowpea) (Lin et al., 1981). 
Approximately 0.2 g of desiccated, infected leaf tissue was 
ground in 2 ml of 0.05 M phosphate buffer (sodium, potasium 
phosphate, pH 7.0) and used to mechanically inoculate leaves 
of 5 cowpea plants which had been dusted with 600 mesh 
carborundum. Fourteen to twenty days later, systemically 
infected leaves were collected and ground in 0.05 M phosphate 
buffer and used to inoculate a large number of cowpea plants 
for virus propagation. 
Purification of Cowpea Severe Mosaic Virus 
The purification procedure described by Lin et al. (1981) 
was modified and used for isolating CPSMV. 
Fourteen days after inoculation, infected cowpea leaves 
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were harvested, weighed and homogenized in 2 volumes of borate 
buffer (0.1 M boric acid, 0.01 M ethylenediamine-tetraacetic 
acid, 0.1% sodium sulfite, pH 7.6) with a Waring blender. The 
homogenate was filtered through two layers of cheesecloth. 
Butanol was added to a final concentration of 8% (vjv) to the 
filtrate. The mixture was incubated at 22 C for 5 minutes and 
then centrifuged at 11,700 x g for 20 minutes. The 
supernatant was strained through glass wool to remove large 
pieces of plant debris. To precipitate the virus, PEG 
(polyethylene glycol, MW 6000) and NaCl were added to final 
concentrations of 6% (wjv) and 0.01 M, respectively. The 
mixture was stirred for 20 to 30 minutes and then stored at 4 
c for 2 hours. The precipitated virus was collected by 
centrifugation at 11,700 x g for 25 minutes. The pellet was 
covered with 0.05 M phosphate buffer and placed on a shaker 
overnight at 4 c. 
Further purification of the virus was achieved by 2 to 3 
cycles of differential centrifugation. The resuspended 
mixture was centrifuged at 8,700 x g for 10 minutes. The 
virus was concentrated from the supernatant by centrifugation 
at 77,600 x g for 2 hours and resuspended in 0.05 M phosphate 
buffer. 
The resuspended virus was centrifuged through a linear 
sucrose gradient [10%, 20%, 30%, 40% sucrose (wjv) solution in 
0.05 M phosphate buffer] using a Beckman SW27 rotor at 65,000 
x g for 1.5 hours. Virus was collected with a density 
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gradient fractionator (Model 640; ISCO, Lincoln, NE) equipped 
with a monitor at 254 nm. The fractionated virus was pooled 
and dialyzed overnight against 0.05 M phosphate buffer. 
Finally, virus was concentrated by centrifuging at 77,600 x g 
for 2 hours and resuspended in 0.05 M phosphate buffer. 
Virus concentration was measured spectrophotometrically 
0.1% by using E 280 = 8.0 (van Kammen, 1971). 
Production of Hybridomas 
Immunization of mice 
BALB/c mice (Jackson Laboratory, BarHarbor, ME) were used 
to produce hybridomas. Fifty ig purified virus (CPSMV III) in 
0.1 ml 0.05 M phosphate buffer was emulsified with an equal 
volume of Freund's complete adjuvant (Sigma Chemical Co., St. 
Louis, MO; #F-5881). Female mice were used and injected with 
virus intraperitoneally. One month later, at an interval of 3 
days, the mice were twice boosted intravenously through the 
tail vein with the same amount of virus. Three days after the 
second hyperimmunization, a mouse was exsanguinated and the 
serum was retained as a positive control for screening assays. 
Media and chemicals used in hybridoma production 
Dulbecco's modified eagle medium CDMEM) DMEM medium 
was the basic nutrient medium which consisted of: 
DMEM (Gibco Laboratories, Grand 
Island, NY; #430-2100) 5 L package 
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N-2-Hydroxyethylpiperazine-N-2-
ethanesulfonic acid (HEPES; 
Sigma #H-3375} 35 g 
18.5 g 
5 L 
The medium was filtered through a 0.4 um Zetapor filter 
(AMF Cuno, Meriden, CT; #NM142-01-020sp) and then through a 
0.2 um Aero 50A filter (Allied Fisher Scientific, Itasca, IL; 
#09-730-241G). The medium was collected and stored at 4 c. 
Regular growth and maintenance medium (DMEM-R) DMEM-R 
was used for the growth, maintenance and revitalization of 
hybridoma cells. It was prepared by adding 1 ml L-glutamine 
solution (0.2 Min H2o), 7.5 to 10 ml of horse-calf serum (2 
parts horse to 1 part calf serum; Gibco Laboratories, Grand 
Island, NY; #230-6050 and #230-6170) into DMEM to a final 
volume of 100 ml. It was filtered through a 0.2 um cellulose 
acetate syringe filter (Allied Fisher Scientific #09-740-35A). 
Myeloma cells The Sp2/0-Ag14 (Sp2/0} myeloma cells 
were originally provided by Dr. R. A. Van Deusen (National 
Veterinary Services Laboratories, Ames, IA}. Cells were 
maintained by transfering to DMEM-R three times a week. 
8-Azaguanine (8-aza) medium 8-aza medium was used to 
eliminate Sp2/0 mutants resistant to aminopterin which arise 
during the regular growth period. 8-aza solution (1X} was 
prepared by adding 10 ml ddH2o to the powder to make a final 
concentration of 6.6 x 10-3 M (Sigma #A-8256}. 8-aza medium 
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was DMEM-R medium containing 1% 8-aza solution (lX). Every 
three months, Sp2/0 cells were passaged through 8-aza medium 
twice. 
Conditioned medium Sp2/0 cells were grown in DMEM-R 
for 3 days until the medium became orange-yellow. Cells were 
concentrated by centrifuging at 2000 rpm for 10 minutes, and 
the conditioned medium was filtered through a 0.2 Im syringe 
filter to eliminate remaining cells. 
HAT medium Hypoxanthine, aminopterin and thymidine 
were used to select spleen-Sp2/0 hybrid cells (Yelton and 
Scharff, 1981). The Sp2/0 myeloma cells lacked the enzyme 
hypoxanthine-guanine phosphoribosyl transferase (HPRT) . They 
could not use exogenous hypoxanthine to synthesize purines, 
and died in the presence of aminopterin, which blocked de novo 
synthesis of purines and pyrimidines. Spleen cells, although 
not killed by aminopterin, could not be cultured indefinitely. 
Therefore, after a few days the only rapidly dividing cells 
remaining were Sp2/0-spleen hybrids. HAT medium consisted of: 
HAT solution (lOOX) (Hazelton-
Dutchland Inc., Denver, 
PA; #59-77076) 
Conditioned medium 
Horse-calf serum 
DMEM 
L-glutamine solution 
1 ml 
50 ml 
10 ml 
38 ml 
1 ml 
HT medium It was made in the same manner as HAT 
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medium except that hypoxanthine-thymidine (HT; Hazleton-
Dutchland Inc. #59-57076) was substituted for HAT. HT medium 
was a transition medium for hybridomas from HAT medium to 
DMEM-R medium. 
Phosphate buffered saline (0.01 M PBS, pH 7.2) 
Dibasic sodium phosphate (0.01 M) containing 0.85% NaCl was 
prepared and titrated to pH 7.2 with 0.01 M monobasic sodium 
phosphate containing 0.85% NaCl. 
Polyethylene glycol (PEG) PEG was utilized to break 
or weaken cell membranes and enhance fusion of cells. PEG 
solution was prepared by adding 2.7 ml of 0.01 M PBS to 2.25 g 
PEG (MW 1000; Hazleton-Dutchland Inc. #59-90739) and 
dissolving in a 60 C water bath. 
Freezing medium This medium was made by adding 10 ml 
dimethyl sulfoxide (DMSO; Sigma #D-2650) to 90 ml of sterile 
horse-calf serum. 
Production of hybridomas 
A modified version of Van Deusen and Whetstone's protocol 
(1981) for MAb production was used. All sterile work was done 
in a laminar flow hood (Baker Co. Inc., Biddle ford, ME). 
Three days prior to cell fusion, Sp2/0 cells were passed 
in DMEM-R medium and the mouse was hyperimmunized for the 
second time. After exsanguination, the spleen was removed 
aseptically. The spleen was rinsed with 5 ml DMEM in the 
first sterile 60 rom plastic petri dish and then transferred to 
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the second petri dish. It was perfused with 5 ml DMEM by 
using a 2 ml syringe. over the third petri dish, the spleen 
tissue was macerated through a 100 mesh stainless steel screen 
and separated into single cells. The medium in the second 
petri dish was used to wash the screen. The spleen cells were 
mixed with Sp2/0 cells at a 1:1 ratio, and were centrifuged at 
200 x g for 8 minutes. One milliliter of sterile PEG solution 
was added to the pellet slowly over a period of 15 seconds. 
The cells were gently mixed for 30 seconds and then incubated 
in a 37 C water bath for 90 seconds. One milliliter of DMEM 
was slowly added to the tube over a period of one minute and 
the tube was rotated gently to mix the cells at the same time. 
After the addition of 10 ml more DMEM, the tube was incubated 
in the 37 C water bath for 5 minutes. The cells were 
collected by centrifuging at 200 x g for 8 minutes. The 
pellet was dispersed in 1 ml HAT medium and then resuspended 
to a concentration of 5 X 105 myeloma cellsjml with 
additional HAT medium. The cell suspension was plated at 0.2 
mljwell in 96-well tissue culture plates (Corning Glass Works, 
Corning, NY; #25860). They were incubated at 37 c in an 
incubator enriched with 5% co2 (Forma Scientific, Marietta, ' 
OH; water-jacketed incubator). 
Four days after fusion, old media in the wells were 
aspirated and new HAT medium was added. Three days later, 
cells were fed with HT medium. Another three days later, they 
were fed with HT medium and thereafter with DMEM-R at 2 to 3 
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day intervals. 
When the bottom of the majority of the wells were one-
half to two-thirds covered with hybridoma cells, the media 
were screened for antibody-producing cells by indirect ELISA. 
Indirect Enzyme-Linked Immunosorbent Assay 
A procedure similar to that described by Voller et al. 
(1976) was used. The buffers used in indirect ELISA were 
prepared in the following manner: 
Virus coating buffer This 0.05 M sodium-potassium-
phosphate buffer (pH 7.0) was the same as the one used in 
virus purification. 
Wash buffer (PBS-Tween, 20X) 
NaCl 
KH2Po4 
Na2HP04 
KCl 
Polyoxyethylenesorbitan 
monolaurate (Tween 20; 
Sigma #P-1379) 
Sodium azide 
dd H2o to a final volume of 
160.0 g 
4.0 g 
23.8 g 
4.0 g 
10.0 ml 
1.0 g 
1000 ml 
ELISA plates were washed with lX wash buffer between 
steps to reduce non-specific binding. Wash buffer was also 
used to prepare blocking buffer and to dilute antibodies. 
Blocking buffer (5% blotto) The excess sites after 
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binding of antigen to the well were blocked by blocking buffer 
to reduce the non-specific binding. 
Non-fat dry milk (Carnation brand) 
Antifoam A emulsion (Sigma #A-5758) 
1X wash buffer to 
5 g 
33.3 ul 
100 ml 
After stirring for 30 minutes, the mixture was filtered 
through Whatman #1 filter paper, and the pH was adjusted to 
7.4. 
Substrate buffer 
Diethanolamine 
MgC1 2 .6H2 0 
Sodium azide 
dd H2o to 
10.0 ml 
10.0 mg 
25 mg 
100 ml 
HCl (1 N) was used to adjust the pH to 9.8. 
One phosphatase substrate tablet (P-nitrophenyl 
phosphate, disodium, 5 mgjtablet; Sigma #104-105) was 
dissolved in 5 ml substrate buffer to prepare the substrate 
solution. 
At a concentration of 0.5 ugjml in coating buffer, 50 ul 
CPSMV III was added to each well of a polystyrene Immulon I 
plate (Dynatech Laboratories, Alexandria, VA). After 
incubation at 37 C for 1 hour, the plate was washed with wash 
buffer three times for 3-5 minutes, and then blocked with 300 
ul of 5% blotto. The plate was incubated at 37 C for 1 hour 
and washed afterwards. Supernatants (50 ul) from the wells of 
tissue culture plates were added and incubated at 37 c for 1 
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hour and washed. Fifty microliter of alkaline phosphatase 
conjugated with rabbit anti-mouse IgG or goat anti-mouse IgM 
antibodies (Sigma #A-7784 and #A-1902, 1:1000 diluted in wash 
buffer), were added to each well. The plate was incubated at 
37 C for 1 hour and washed. After 50 ul substrate solution 
was added, the plate was incubated at 37 C for 30 to 60 
minutes or until a yellow color change was observed. 
Reactions were stopped by adding 50 ul of 3 N NaOH to each 
well. The reaction product could be observed visually for 
color change from colorless to yellow, or it could be measured 
photometrically at 410 nm with a Dynatech Minireader II 
(Dynatech Laboratories). Hyperimmune serum was used as a 
positive control and conditioned medium as a negative control. 
The cells in the positive wells were saved for cloning. 
Cloning 
Two kinds of cloning procedures were used in this study. 
The first procedure (limiting dilution) was as described by 
Mernaugh et al. (1987). The hybridoma cells growing in tissue 
culture plates selected by indirect ELISA were resuspended and 
one drop of the cell suspension was transferred to 5.0 ml of 
DMEM-R (10-2 dilution). One drop of this mixture was 
transferred to the second 5 ml DMEM-R and mixed (10-4 
dilution). Again, another 0.5 ml of cell suspension was added 
to 4.5 m1 DMEM-R in the third tube (10-5 dilution). The 
second and the third cell suspension were plated at 0.2 
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mljwell into 96-well tissue culture plates. 
The second procedure (calculation method) was as follows. 
After the hybridoma cells were counted, they were diluted in 
20 ml DMEM-R to a final concentration of 5 cellsjml. Two-
tenths milliliter of cell suspension (1 cell/0.2 ml) were 
added to each well of a 96-well tissue culture plate. 
The plate was incubated in the 37 c incubator enriched 
with 5% co2 and high humidity. Wells containing single cell 
colonies were selected under a light microscope. When the 
bottom of wells was two-thirds covered with cells, the culture 
medium was tested by indirect ELISA for the production of 
relevant MAbs. The positive clones were expanded in DMEM-R 
medium. After the immunoglobulin class and subclass of MAbs 
were determined, cells were frozen or injected into mice to 
produce ascitic fluid. 
Isotyping of Monoclonal Antibody 
A Streptavidin-Biotin SystemjMonoAb-ID EIA Mouse Kit 
(Zymed Lab. INC., San Francisco, CA) was utilized to determine 
the immunoglobulin class and subclass in a modified indirect 
ELISA. 
The ELISA plate was coated with virus antigen, blocked 
with 5% blotto, and MAb in DMEM-R medium was added as in the 
indirect ELISA. Fifty microliter of biotinylated normal 
rabbit immunoglobulin (as negative control) or rabbit anti-
mouse IgM (immunoglobulin M), IgG, IgG2a, IgG2b, IgG3 and IgA 
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(immunoglobulin A) were added to each well. The plate was 
incubated at 37 c for 30 minutes and washed with wash buffer. 
Peroxidase-labeled streptavidin (50 uljwell) was added to all 
wells. After incubation at 22 C for 30 minutes and washing, 
100 ul of ABTS solution [2, 2-azino-di (3-ethyl benzthiazoline 
sulfonic acid)] was added and incubated at 22 c. The reaction 
products were determined with a spectrophotometer at 410 nm. 
Freezing Cells 
Hybridoma cells were centrifuged at 200 x g for 8 min and 
resuspended in 2 ml DMSO medium. Cells were transferred into 
an autoclaved Nunc tube (Nunc-Vangard International; Neptune, 
NJ) . Nunc tubes were put into a grey Nunc mainer which was 
fitted inside a styrofoam freezing chamber. They were 
designed to let the temperature drop by 1 Cjmin until 
-100 C was achieved. They were placed in a -100 c cryogenic 
freezer. The second day, the tubes were removed from the 
styrofoam chamber and the Nunc mainer and stored at -100 c. 
To revitalize the frozen cells, the Nunc tube was warmed 
rapidly between the palms of hands. The contents were 
centrifuged at 200 x g for 6 minutes. Cells were washed once 
with DMEM-R medium by centrifugation, resuspended in DMEM-R 
and plated in 96-well plate. 
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Production of Monoclonal Antibody 
Flask media and mouse ascitic fluid were used as a source 
of MAbs. 
To prepare flask media, cells were grown in DMEM-R medium 
for 14 to 20 days. The flask media were centrifuged at 1000 x 
g for 10 minutes, and the supernatants were stored at -70 c. 
Mice were utilized to produce ascitic fluid which 
contained a higher concentration of specific MAb than did 
flask media. BALB/c mice were primed with 0.5 ml tetramethyl 
pentadecane (pristane; Sigma #T-7640) one month prior to the 
injection of cells. One half milliliter of actively growing 
cloned cells (approximately 1 X 106 cellsjml) were 
centrifuged, resuspended in 0.5 ml of PBS, and were injected 
into the peritoneal cavity of the recipient mouse. Ten to 
fifteen days later, when the peritoneal swelling became 
pronounced, ascitic fluid was collected at 2-to 3-day 
intervals by inserting an 18 G needle into the peritoneal 
cavity. The ascitic fluid was clarified by centrifugation at 
1000 x g for 10 minutes and stored at -20 c. 
Purification of Monoclonal Antibody 
Purification of IgM through a sepharose column 
Monoclonal IgM was purified from ascitic fluid using the 
procedure described by Jones et al. (1988). Ascitic fluid was 
added dropwise to 0.32 M boric acid with gentle stirring 
(ascitic fluid:boric acid= 1:20, vjv). After incubation at 
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22 C for 30 minutes, the precipitated antibody was centrifuged 
at 800 x g for 10 minutes. The pellet was resuspended in 0.1 
M Tris-HCl, pH 8.0, containing 0.15 M NaCl (0.1 M Tris 
buffer), and dialyzed against the same buffer overnight. The 
mixture was chromatographed on a Sepharose CL-6B gel 
filtration column (Pharmacia, Inc., Piscataway, NJ; 58 em X 
1.5 em, Vo = 35.0 ml), using 0.1 M Tris buffer as the elution 
buffer. IgM, as the largest protein molecule, emerged in the 
first peak. One milliliter fractions, after the void volume, 
were collected and assayed by indirect ELISA for the presence 
of specific IgM. Protein concentration of MAb was estimated 
by using 
0.1% 
E260 = 1.4. 
Purification of IgM through anti-IgM affinity column 
Alternatively, another procedure was used to purify IgM 
from ascitic fluid. The chromatography column was constructed 
by using a 10 ml syringe which contained 5 ml wet volume of 
anti-mouse IgM (u-chain specific) agarose (0. 4 mg of mouse IgM 
could be bound and eluted per milliliter resin; Sigma #A4540). 
The column was washed with 0.01 M PBS (pH 7.4). The ascitic 
fluid was adjusted to pH 7.4 and applied to the column. After 
washing with 20 ml of pH 7.4 PBS (0.01 M) and 10 ml pH 4.0 PBS 
(0.01 M), the bound IgM was eluted from the column in the 
second peak by washing with an appropriate amount of pH 3.0 
PBS (0.01 M). The fractions were adjusted to pH 7.0 with 0 . 01 
M NaOH and tested with an indirect ELISA for the presence of 
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IgM. The fractions that contained IgM were pooled and 
dialyzed overnight against 0.01 M PBS (pH 7.0). 
Biotinylation of Monoclonal Antibody 
The purified antibody was biotinylated by the method of 
Bayer et al. (1979). N-hydroxysuccinimidobiotin (biotin; 
Sigma #H-1759) dissolved in dimethylforrnamide (DMF) was added 
to monoclonal IgM in a 1:50 v j v and 20:1 mol j mol ratio. The 
mixture was rotated at 22 C for 4 hours, and was dialyzed at 4 
C against 0.01 M PBS (pH 7.0) overnight. The concentration of 
biotinylated MAb was measured spectrophotometrically at 
E~s~%= 1.4. It was stored in 1 ml aliquots at -20 c. 
Competition Enzyme-Linked Irnrnunosorbent Assay 
Optimization for competition ELISA 
Indirect ELISA was used to optimize the concentrations of 
coating antigen, biotinylated antibody and avidin-labeled 
alkaline phosphatase. The plates were incubated at 37 C for 1 
hour at each step and then washed with wash buffer in all the 
competition ELISA assays. The optimized conditions were 
achieved by calculation of P/N ratios (Hill et al., 1981) to 
yield the highest response (P) over background (N) . The 
optimization procedures were as follows. 
To optimize the concentration of coating antigen, 
purified virus was added to an ELISA plate at concentrations 
of 0.25, 0.5, 2, 5, 8, 10, 15, 20, 25 and 30 ugjml (6 wells 
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per concentration). After the plate was blocked, 5 ugjml (50 
uljwell) biotinylated antibody was added to each of 3 wells at 
each antigen concentration; wash buffer was added to the other 
3 wells as a control. Avidin-labeled alkaline phosphatase (2 
ugjml) and substrate were added stepwise. The P/N ratios were 
calculated as the ratio of the average absorbance in the 
presence of biotinylated antibody to that in the absence of 
biotinylated antibody. The concentration that had the highest 
P/N ratio was considered to be the optimum concentration. 
To optimize the concentration of biotinylated antibody, 
antigen at the optimum concentration was applied to half of 
the wells in an Immulon I ELISA plate (50 uljwell), 0.05 M 
sodium-potassium phosphate buffer (pH 7.0) was added to the 
other half of the wells as a control. After blocking the 
plate, 50 uljwell of biotinylated antibody was added at 
concentrations of 0.5, 1, 2, 3, 4, 5, 6 ugjml (six wells for 
each concentration; three wells contained antigen and the 
other three contained sodium-potassium phosphate buffer) . 
Then, 50 uljwell of avidin-alkaline phosphatase (2 ugjml) were 
added, followed by substrate after one hour. The P/N ratios 
were calculated as the ratio of the average absorbance in the 
presence of antigen to that in the absence of antigen. 
To optimize the concentration of avidin-labeled alkaline 
phosphatase, antigen and biotin labelled antibody at optimum 
concentrations were added to an ELISA plate sequentially. 
Dilutions of avidin-alkaline phosphatase at 0.5, 1, 2, 3, 4, 
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5, and 6 ugjml were added to each of 6 wells per 
concentration. Three wells contained antigen, the other three 
wells contained 0.05 M sodium-potassium phosphate buffer. The 
P/N ratio was measured as the ratio of the average absorbance 
in the presence of antigen to that in the absence of antigen. 
Simultaneous and consecutive competition ELISA 
Simultaneous and consecutive competition ELISA were used 
as described by Kubanek (1987). Immulon I ELISA plates were 
coated with antigen (50 uljwell) at the optimum concentration 
and blocked with 5% blotto. In the simultaneous assay, serial 
two-fold dilutions of unlabeled antibody (flask media) ranging 
from undiluted to 1:1024 were added (50 uljwell) together with 
biotinylated antibody (50 uljwell) at the optimum 
concentration. In some cases, the competitive ability of 
unlabeled antibodies was not exhausted at 1:1024 dilution. 
Therefore, another set of dilutions was used which included 
1:5, 1:10, 1:50, 1:100, 1:250, 1:500, 1:1000, 1:5000, 1:25000 
and 1:10000. In the consecutive assay, these two reagents 
were added stepwise; i.e., after incubation with unlabeled 
antibody at 37 C for one hour followed by washing, labeled 
antibody was added to the plates which were then incubated at 
37 c. Then, 50 uljwell avidin-labeled alkaline phosphatase at 
the optimum concentration was added, followed by the addition 
of substrate solution. In these assays, plates were incubated 
at 37 C for 1 hour after addition of each reagent and washed 
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with wash buffer three times. The reaction products were 
measured at 410 nm. 
In both assays four wells, which contained all the 
reagents except the unlabeled antibody, were used as positive 
controls. These were designated as having maximum binding 
(100% absorbance). Four other wells, containing all the 
reagents except antigen (for which 0.05 M phosphate buffer, pH 
7.0 was substituted) and unlabeled antibody, were used as a 
negative control to assess whether the biotinylated antibody 
reacted non-specifically with the blocking agent. 
The competition between labeled and unlabeled antibody 
for binding to antigen was assessed by calculating the percent 
maximum absorbance (PMA). Since the positive control was 
designated at 100% absorbance, the maximum absorbance would be 
reduced if the unlabeled antibody competed with the labeled 
antibody. The PMA was equal to the average absorbance of the 
sample divided by the average absorbance of the positive 
control. 
It was assumed that the unlabeled antibody did not 
compete with the biotinylated antibody if, in both assays, PMA 
was greater than 75% at all dilutions of unlabeled antibody. 
Furthermore, greater competition in the simultaneous assay 
indicated that concentration of the unlabeled antibody had a 
greater effect on its ability to compete, while greater 
competition in the consecutive assay indicated that affinity 
had a greater impact. The results of these two assays also 
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provided evidence for the number of binding sites that the 
unlabeled antibody competed for on the antigen. When the 
consecutive andjor simultaneous assay curves were diphasic, 
the antibodies probably bound to two sites; if both the 
consecutive and simultaneous assay curves were monophasic, the 
antibodies competed for one site. 
Antigens in competition ELISAs included CPSMV, serotypes 
I, II and III. MAbs used in competition assays included 
antibodies 6A, 5B, E2, Fl, GlO and H6 produced against CPSMV I 
by Dr. J. H. Hill, Iowa State University, Ames, IA; 2-7A, 2-
llA, 4-SB, 3-9C, 3-llC, 2-lF, 4-SF, 4-6F, l-9G, 1-llG, 2-llG 
produced against CPSMV II by c. A. Kubanek; and 5B5, 6B3, 5C6, 
408, 3E7, 2Hl0 produced against CPSMV III by the author. 
In the first set of competition assays, CPSMV I was the 
coating antigen. MAb 5B was selected and biotinylated, 
because it had a very strong binding capacity to CPSMV I as 
determined in competition assays (Kubanek, 1987). 
In the second set of competition assays, CPSMV II was the 
antigen and MAb 4-5B was used as the biotinylated antibody 
because it did not compete with MAb 5B in the first set of 
assays. 
In the third set of competition assays, CPSMV III was the 
antigen. MAb 5B5 was the labeled antibody since it did not 
compete with MAbs 5B and 4-SB. 
Based on the competitive characteristics of a total of 23 
MAbs in simultaneous and consecutive competition assays, seven 
38 
MAbs (5B, 6A, 4-5B, 4-6F, 5B5, 408, 5C6) were chosen to form a 
panel for the signature analysis assays. However, MAbs 6A, 4-
6F, 408 and 5C6 were not labeled with biotin and assayed in 
the simultaneous and consecutive competition ELISAs like MAbs 
5B, 4-5B and 5B5. In order to further elucidate the 
competitive abilities of the seven MAbs used in the panel 
against each other, a simple antibody competition assay was 
performed. Fifty microliter per well of 15 ugjml CPSMV I or 
II and 10 ugjml CPSMV III, as optimized previously, were added 
separately into Oynatech Immulon I plates. Plates were 
incubated at 37 c for one hour and washed. After blocking 
with 5% blotto, 50 uljwell of biotinylated antibodies were 
added at optimized concentrations (5 ugjml of MAbs 5B, 6A, 4-
5B, 4-6F, 5B5, 5C6; 6 ugjml of MAb 408} to the wells which 
contained homologous virus serotypes (i.e., MAbs 5B, 6A into 
wells with CPSMV I; MAbs 4-5B, 4-6F into wells with CPSMV II; 
MAbs 408, 5C6 into wells with CPSMV III). Simultaneously, 50 
uljwell of these seven unlabeled purified MAbs with the same 
concentrations as the biotinylated antibodies, were added into 
the wells containing labeled MAb 5B, 6A, 4-5B, 4-6F, 5B5, 408 
or 5C6. After incubation at 37 C for one hour and washing, 3 
ugjml avidin-labeled alkaline phosphatase was applied to the 
wells followed by the alkaline phosphatase substrate. 
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Signature Analysis 
In the signature analysis assays by Wands et al. (1984), 
polystyrene beads were used as the solid phase, and the MAbs 
were directly labeled with 125I to generate signals. However, 
the 125I-labeling (Iodo-beads, Enzymobead and chloramine T 
methods) of MAbs to CPSMV I, II, III was not successful 
(author's unpublished results). The primary reason was that 
all the MAbs were IgM, and they lost immunoreactivity after 
labeling with 125I as determined by testing immunoreactivity 
of the 125I-labeled MAb by indirect ELISA. In addition, 
polystyrene beads did not seem to be an effective solid phase 
for the binding of antibodies and CPSMV antigens. Therefore, 
a modification of the signature analysis procedure was 
performed. 
MAb 408 was selected as the capture antibody, because it 
was shown to give the highest reading (binding ability) among 
the seven antibodies for binding to CPSMV I, II, III and IV in 
an indirect ELISA test. The optimum concentration of MAb 408 
was determined by diluting ascitic fluid of MAb 408 from 1:2 
to 1:2 26 in 0.01 M PBS (pH 7.4). Dilutions were added to 
Dynatech Immulon I removawell strips (# 011-010-6301, 50 
uljwell) which were incubated at room temperature overnight. 
After blocking with 5% blotto, 50 ul of of CPSMV I infected 
cowpea (diluted to 1:216 ) and healthy cowpea extracts were 
applied. Phosphate buffer (sodium-potassium phosphate buffer, 
0.05 M, pH 7.0) was added as a control. After incubation at 
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37 C and washing, 5 ugjml of biotinylated MAb 6A diluted in lX 
wash buffer was added to the plate, followed by 200,000 cpm 
125I-labeled avidin (Amersham Corporation, Arlington Heights, 
IL; # IM.236). The strips were washed with wash buffer by 
using a Pentawash (Abbott Laboratories, North Chicago, IL.). 
Single wells were separated and transferred into glass tubes. 
The bound radioactivity (cpm) was counted with a gamma counter 
(Tracer Analytic Model 1191 Automatic Gamma System) and the 
P/N ratio was calculated. 
The optimum concentrations for seven MAbs used in 
signature analysis were determined as in the simultaneous and 
consecutive competition ELISAs. 
For the signature analysis assay, 50 ul of a 1:4000 
dilution of MAb 4D8 ascitic fluid (in 0.01 M PBS, pH 7.0) was 
added to each well of the removawell strips. The strips were 
incubated at 22 C overnight, washed and blocked with 300 
uljwell of 5% blotto. After incubating one hour at 37 C and 
washing, serial (two-fold) dilutions (1:2, 1:4, •.. , 1:2048; 
. 1 1 1.e., :2 , ••• , 1:211) of fresh CPSMV-infected leaf extracts 
in sodium-potassium phosphate buffer were added at 50 uljwell. 
The extracts were prepared fresh each time by grinding one 
gram of infected (CPSMV I to IX) leaves in 1 ml of 0.05 M 
sodium-potassium phosphate buffer, and straining through two 
layers of cheese-cloth (the undiluted sample). Extracts from 
uninocu1ated cowpea leaves were prepared in the same way for 
use as a negative control. The strips were incubated at 37 c 
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for one hour and then washed with wash buffer. Seven 
biotinylated MAbs SB, 6A, 4-SB, 4-6F, SBS, 4D8 and 5C6 were 
added to the wells (50 uljwell) seperately at 5 ugjml in wash 
buffer. After incubation at 37 c for 1 hour, the strips were 
washed and 200,000 cpmjwell of 125r-labeled avidin in wash 
buffer was added. After incubation at 22 C for one hour, 
wells were washed by using a Pentawash and the wells were 
separated and the bound radioactivity was counted with a gamma 
counter. In every experiment, the antigenic signatures of 
each antigen were generated simultaneously with seven MAbs in 
three replicates. These signatures were replicated three 
times with different samples, i.e., with three different 
preparations of the virus antigen. 
For each serotype of CPSMV, binding curves (signatures) 
were established, with seven MAbs, by plotting LN (CPM/CK} 
(mean CPM bound in the test sample I mean CPM bound in healthy 
control by the dilution equivalent to the check) versus the 
exponential values of two-fold dilutions of antigen. Since 
the absolute concentration in each virus sample was not 
standardized, a statistical (iterative least-squares) 
technique was used to estimate the multiple response functions 
between LN (CPM/CK} and dilution factors. The statistical 
methods used in the iterative alignment and curve-fitting 
procedures have been described in detail by Ben-Porath et al. 
(1985}. Data, LN (CPM/CK} and exponential values of two-fold 
dilution of antigens, were analyzed by a computer program, and 
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computer-graphic plots of aligned binding curves were 
generated. When aligned binding curves of two or more 
serotypes of CPSMV with a MAb were superimposable, they were 
considered to have a quantitatively and qualitatively 
identical epitope. 
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RESULTS 
Purification of Cowpea Severe Mosaic Virus 
The yields of CPSMV III obtained by differential and 
sucrose gradient centrifugation were very satisfactory. 
Yields ranged from 50.7 mg to 137 mg virus per kilogram of 
leaf tissue. 
Production of Monoclonal Antibody 
Two fusions were performed using CPSMV III as the 
immunogen. In the first fusion, about 70% of the wells 
contained fused cells, of which 20% produced antibodies 
specific to CPSMV III. After cloning with the limiting 
dilution procedure three times, four clones (2HlO, 3E7, 5B5, 
5C6) were selected which continued to secrete MAbs to CPSMV 
III. In the second fusion, hybridomas were cloned by using 
the calculation method and the two clones 4D8 and 6B3 were 
selected. 
The selected clones were expanded in DMEM-R medium to 
produce flask media and were injected into mice to produce 
ascitic fluid. They were also frozen in DMSO medium and 
stored at -100 C. 
Isotyping of Monoclonal Antibody 
The class and subclass of MAbs produced by the selected 
cell lines were determined by the isotyping kit from Zymed 
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Laboratories. All 23 MAbs used in competition ELISAs produced 
IgM. 
Purification of Antibodies 
The yield of MAbs purified from 1 ml of ascitic fluid by 
precipitation with 0.32 M boric acid was approximately in the 
range from 0.5 mg to 5 mg IgM while the yield of antibodies 
purified on an A-mouse IgM affinity column ranged from 0.06-2 
mg IgM/ml ascitic fluid. 
Competition Enzyme-Linked Immunosorbent Assays 
The optimum concentration of coating antigens, 
biotinylated antibodies and avidin-alkaline phosphatase were 
determined by calculating the P/N ratios in indirect ELISA. 
In the three sets of competition ELISAs, they were 15 ugjml 
CPSMV I, 5 ugjml biotinylated MAb 5B and 3 ugjml avidin-
alkaline phosphatase; 15 ugjml CPSMV II, 5 ugjml biotinylated 
MAb 4-5B and 5 ugjml for avidin-alkaline phosphatase; and 10 
ugjml for CPSMV III (Fig. 1), 5 ugjml for biotinylated MAb 5B5 
and 2 ugjml for avidin-alkaline phosphatase. 
Results of competition experiments for seven MAbs used in 
the panel are summarized in Table 1. They were results of at 
least two independent experiments. The competition curves for 
these seven MAbs are shown in Figs. 2 to 8. Competition 
curves for the other MAbs are shown in Appendix A. 
From the results of simultaneous and consecutive 
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Figure 1. Determination of the optimum virus concentration 
(CPSMV III) for competition ELISA assays. This 
was determined by calculating the P/N ratio (A--
•) which was the ratio of the absorbance of the 
positive control (o--o) divided by negative 
control (•--•) 
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Table 1. Competition between monoclonal antibodies for 
binding sites on CPSMV I, II and III 
Unlabeled 
MAb 
5B 
6A 
E2 
F1 
G10 
H6 
4-5B 
2-7A 
2-11A 
3-9C 
3-11C 
2-1F 
4-5F 
4-6F 
1-9G 
1-11G 
2-11G 
5B5 
2H10 
3E7 
408 
5C6 
6B3 
Antigen Serotypes + Biotinylated MAbs 
CPSMV I + 5B 
+ 
+b I 
I 
I 
I 
I 
I 
+ 
+ 
c 
+ 
1 
2 
2 
2 
1 
2 
I 2 
+ I 1 
+ I 1 
+ I 2 
I 2 
+ I 2 
+ I 1 
I 1 
+ I 1 
+ I 2 
+ I 2 
I 1 
+ I 1 
+ I 1 
+ I 1 
+ I 2 
+ I 1 
CPSMV II + 4-5B CPSMV III + 5B5 
Competition 1 Shape of Curvea 
+ I 
+ I 
I 
+ I 
+ I 
+ I 
2 
1 
1 
2 
1 
2 
+ I 2 
+ I 1 
+ I 2 
+ I 1 
+ I 1 
+ I 2 
+ I 1 
+ I 1 
+ I 2 
I 2 
+ I 2 
I 1 
+ I 1 
+ I 2 
I 2 
+ I 2 
+ I 2 
+ I 2 
+ I 2 
+ I 2 
+ I 2 
+ I 2 
+ I 2 
+ I 2 
+ I 1 
+ I 2 
+ I 2 
+ I 2 
+ I 2 
+ I 2 
+ I 2 
+ I 2 
+ I 2 
+ I 2 
+ I 1 
+ I 1 
+ I 2 
+ I 1 
+ I 2 
+ I 1 
ashape of competition curves is designated as (1) 
monophasic if both simultaneous and consecutive curves are 
monophasic; or as (2) if the simultaneous andlor consecutive 
curve is diphasic. 
b+ indicates that the unlabeled MAb competed with 
biotinylated MAb for sites on the antigen in at least one 
competition (simultaneous or consecutive) assay. 
c_ indicates that the unlabeled MAb did not compete with 
biotinylated MAb in both simultaneous and consecutive 
competition assays. 
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Figure 2. Competition profiles of MAb 5B with biotin-
labeled MAbs in simultaneous (•--•) and 
consecutive (4--~) competition ELISAs. MAbs were 
made to CPSMV. 5B(l): competition between 5B and 
labeled 5B using CPSMV I. 5B(2): competition 
between 5B and labeled 4-5B using CPSMV II. 
5B(3): competition between 5B and labeled 5B5 
using CPSMV III. Percent maximum absorbance is 
equal to the average absorbance of the sample 
divided by the average absorbance of the positive 
control 
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Figure 3. Competition profiles of MAb 6A with biotin-
labeled MAbs in simultaneous (•--•) and 
consecutive (A--~) competition ELISAs. MAbs were 
made to CPSMV. 6A(l): competition between 6A and 
labeled 5B using CPSMV I. 6A(2): competition 
between 6A and labeled 4-5B using CPSMV II. 
6A(3): competition between 6A and labeled 5B5 
using CPSMV III. Percent maximum absorbance is 
equal to the average absorbance of the sample 
divided by the average absorbance of the positive 
control 
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Figure 4. Competition profiles of MAb 4-SB with biotin-
labeled MAbs in simultaneous (•--•) and 
consecutive (•--A) competition ELISAs. MAbs were 
made to CPSMV. 4-SB(l): competition between 4-SB 
and labeled 5B using CPSMV I. 4-5B(2): 
competition between 4-SB and labeled 4-SB using 
CPSMV II. 4-5B(3): competition between 4-SB and 
labeled 5B5 using CPSMV III. Percent maximum 
absorbance is equal to the average absorbance of 
the sample divided by the average absorbance of 
the positive control 
53 
140 
120 • ., 
(,) 
c:: 
100 0 -e 
0 ., ao ~ 
E 60 ::l 
E x 
c 40 :::1 
;,It 
20 4-58 (1) 
0 
0 2 .3 4 5 6 7 8 9 10 11 12 
Antibody DDutfon (2-x+ 1) 
140 
120 
Ill 
1.) 
c:: 100 0 -e 
0 ., 
80 ~ 
E 60 ::l 
E x 
c 40 
:::1 
;,It 
4-58 (2) 20 
0 
0 2 .3 4 5 6 7 8 9 10 , 1 12 
Antibody DUutfon (2-x+ 1) 
140 
120 
e 
(,) 
c:: 100 0 -e 
0 
e 80 ~ 
E so ::l 
E x 
0 40 
:::::e 
~ 
20 4-58 (3) 
0 
0 2 3 4 5 6 7 a 9 10 11 12 
Antibody DUutfon (2-1'+ 1) 

Figure 5. Competition profiles of MAb 4-6F with biotin-
labeled MAbs in simultaneous (•---•) and 
consecutive (•---~) competition ELISAs. MAbs were 
made to CPSMV. 4-6F(l): competition between 4-6F 
and labeled 5B using CPSMV I. 4-6F(2): 
competition between 4-6F and labeled 4-5B using 
CPSMV II. 4-6F(3): competition between 4-6F and 
labeled 5B5 using CPSMV III. Percent maximum 
absorbance is equal to the average absorbance of 
the sample divided by the average absorbance of 
the positive control 
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Figure 6. Competition profiles of MAb 5B5 with biotin-
labeled MAbs in simultaneous (•--•) and 
consecutive (4--~) competition ELISAs. MAbs were 
made to CPSMV. 5B5(1): competition between 5B5 
and labeled 5B using CPSMV I. 5B5(2): 
competition between 5B5 and labeled 4-SB using 
CPSMV II. 5B5(3): competition between 5B5 and 
labeled 5B5 using CPSMV III. Percent maximum 
absorbance is equal to the average absorbance of 
the sample divided by the average absorbance of 
the positive control 
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Figure 7. Competition profiles of MAb 4D8 with biotin-
labeled MAbs in simultaneous (•--•) and 
consecutive (A--•) competition ELISAs. MAbs were 
made to CPSMV. 4D8(1): competition between 4D8 
and labeled 5B using CPSMV I. 4D8(2): 
competition between 4D8 and labeled 4-5B using 
CPSMV II. 4D8(3): competition between 4D8 and 
labeled 5B5 using CPSMV III. Percent maximum 
absorbance is equal to the average absorbance of 
the sample divided by the average absorbance of 
the positive control 
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Figure 8. Competition profiles of MAb 5C6 with biotin-
labeled MAbs in simultaneous (•--•) and 
consecutive (•--•) competition ELISAs. MAbs were 
made to CPSMV. 5C6(1): competition between 5C6 
and labeled 5B using CPSMV I. 5C6(2): 
competition between 5C6 and labeled 4-5B using 
CPSMV II. 5C6(3): competition between 5C6 and 
labeled 5B5 using CPSMV III. Percent maximum 
absorbance is equal to the average absorbance of 
the sample divided by the average absorbance of 
the positive control 
61 
140 
120 ., 
u 
c 100 a -e 
0 • !0 .. ~ • 
E 
::l 60 
E x a 40 
::::::1 
lilt 
20 5C6 (1) 
0 
0 2 J 4 5 8 7 8 9 10 11 12 
Antibody OUutlon (2-x+ 1) 
140 
120 
Cl u 
c 
100 a -e 
0 
Ill !0 ~ 
E 60 ::l .s 
X 
a 40 
::::::1 
lilt 
.5C8 (2) 20 
0 
0 2 J 4 5 8 7 8 9 10 11 12 
Antibody DUutlon (2-x+ 1) 
140 
120 
Cl 
0 
c 100 a -e 
0 
Ill 80 ~ 
E 60 ::l 
E x 
40 0 
::::::1 
lilt 
20 5C8 (J) 
0 
0 2 J 4 5 8 7 ! 9 10 11 12 
Antibody DUutlon (2-x+ 1) 
62 
competition ELISAs, seven MAbs were chosen for use in 
signature analysis assays. They were MAbs 5B, 6A, 4-5B, 4-6F, 
5B5, 4D8 and 5C6. MAbs 6A, 4-6F, 4D8 and 5C6 were not 
biotinylated and used in simultaneous and consecutive 
competition ELISAs. In order to further characterize the 
competitive ability of these seven MAbs, a simple competition 
assay was carried out. The results are summarized in Table 2. 
Signature Analysis 
The concentration of the capture MAb 4D8, determined by 
calculating the maximum P/N ratio for the response of the 
CPSMV I infected samples to that of the uninocualted cowpea 
samples (Figure 9), was optimal at a 1:4000 dilution of 
ascitic fluid. 
The concentration for all seven biotinylated antibodies 
(5B, 6A, 4-5B, 4-6F, 5B5, 4D8, 5C6) used in signature analysis 
was chosen as 5 ugjml because it was the optimum concentration 
for six out of seven antibodies, as determined by calculation 
of P/N ratios in simultaneous and consecutive competition 
ELISAs. 
The antigenic signature for each serotype of CPSMV was 
generated with three different virus preparations (Appendix 
B) . Antigenic signatures of all nine (I to IX) serotypes of 
CPSMV are shown in Figures 10-45. When each two of nine 
serotypes of CPSMV are directly compared, each serotype shows 
distinct binding profiles at multiple epitopes which are 
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Table 2. Competition between seven monoclonal antibodies 
as determined by antibody competition ELISAs 
Antigen 
CPSMV I CPSMV II CPSMV III 
Unlabeled 
MAb 
5B 
6A 
4-5 
4-6F 
5B5 
4D8 
5C6 
5B 6A 
++a +++ 
+ +++ 
+ ++ 
++ ++ 
+ ++ 
+ + 
+ + 
Biotinylated MAb 
4-5B 4-6F 5B5 
+++ +++ ++ ++ 
++ ++ ++ ++ 
++ ++ ++ ++ 
++ ++ ++ ++ 
++ ++ ++ ++ 
+ ++ ++ ++ 
+ ++ ++ ++ 
acompetition of unlabeled MAbs by 30-45% (+), 45-60% 
(++), 60-80% (+++) against biotinylated MAbs for antigenic 
sites on CPSMV I, II and III. 
++ 
++ 
++ 
+ 
++ 
++ 
++ 
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Figure 9. Optimization of 
MAb 408 ascitic 
by ELISA. Five 
and 200,000 cpm 
for the signal. 
the mean cpm of 
mean cpm of the 
the concentration of capture 
fluid for sighature analysis 
y~~ml of biotinylated MAb 6A 
I-labeled avidin were used 
P/N ratio was calculated as 
CPSMV I sample divided by the 
healthy cowpea control 
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Figure 10. Antigenic signatures of CPSMV I (the solid 
line) and CPSMV II (the dotted line) using 
MAbs 5B, 6A, 4-5B, 4-6A, 5B5, 408 and 5C6. 
Data are graphed with LN(CPM/CK} on the X-
axis versus the exponential values of two-
fold dilutions of antigen on the Y-axis 
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Figure 11. Antigenic signatures of CPSMV I (the solid 
line) and CPSMV III (the dotted line) using 
MAbs 5B, 6A, 4-5B, 4-6A, 585, 408 and 5C6. 
Data are graphed with LN{CPM/CK) on the X-
axis versus the exponential values of two-
fold dilutions of antigen on the Y-axis 
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Figure 12. Antigenic signatures of CPSMV I (the solid 
line} and CPSMV IV (the dotted line} using 
MAbs 5B, 6A, 4-5B, 4-6A, 5B5, 408 and 5C6. 
Data are graphed with LN(CPM/CK} on the X-
axis versus the exponential values of two-
fold dilutions of antigen on the Y-axis 
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Figure 13. Antigenic signatures of CPSMV I (the solid 
line) and CPSMV V (the dotted line) using 
MAbs 5B, 6A, 4- 5B, 4-6A, 5B5, 408 and 5C6. 
Data are graphed with LN(CPM/CK) on the X-
axis versus the exponential values of two-
fold dilutions of antigen on the Y-axis 
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Figure 14. Antigenic signatures of CPSMV I (the solid 
line) and CPSMV VI (the dotted line) using 
MAbs 5B, 6A, 4-5B, 4-6A, 5B5, 408 and 5C6. 
Data are graphed with LN(CPM/CK) on the X-
axis versus the exponential values of two-
fold dilutions of antigen on the Y-axis 
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Figure 15. Antigenic signatures of CPSMV I (the solid 
line) and CPSMV VII (the dotted line) using 
MAbs 5B, 6A, 4-5B, 4-6A, 5B5, 4D8 and 5C6. 
Data are graphed with LN(CPM/CK) on the X-
axis versus the exponential values of two-
fold dilutions of antigen on the Y-axis 
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Figure 16. Antigenic signatures of CPSMV I (the solid 
line) and CPSMV VIII (the dotted line) using 
MAbs 5B, 6A, 4-5B, 4-6A, 5B5, 408 and 5C6. 
Data are graphed with LN(CPM/CK) on the X-
axis versus the exponential values of two-
fold dilutions of antigen on the Y-axis 
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Figure 17. Antigenic signatures of CPSMV I (the solid 
line) and CPSMV IX (the dotted line) using 
MAbs 5B, 6A, 4-5B, 4-6A, 5B5, 4D8 and 5C6. 
Data are graphed with LN(CPM/CK) on the X-
axis versus the exponential values of two-
fold dilutions of antigen on the Y-axis 
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Figure 18. Antigenic signatures of CPSMV II (the solid 
line) and CPSMV III (the dotted line) using 
MAbs 5B, 6A, 4-5B, 4-6A, 585, 408 and 5C6. 
Data are graphed with LN(CPM/CK} on the X-
axis versus the exponential values of two-
fold dilutions of antigen on the Y-axis 
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Figure 19. Antigenic signatures of CPSMV II (the solid 
line) and CPSMV IV (the dotted line) using 
MAbs 5B, 6A, 4-SB, 4-6A, 5B5, 408 and 5C6. 
Data are graphed with LN(CPM/CK) on the X-
axis versus the exponential values of two-
fold dilutions of antigen on the Y-axis 
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Figure 20. Antigenic signatures of CPSMV II (the solid 
line) and CPSMV V (the dotted line) using 
MAbs 5B, 6A, 4-5B, 4-6A, 5B5, 4D8 and 5C6. 
Data are graphed with LN(CPM/CK) on the X-
axis versus the exponential values of two-
fold dilutions of antigen on the Y-axis 
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Figure 21. Antigenic signatures of CPSMV II (the solid 
line) and CPSMV VI (the dotted line) using 
MAbs 5B, 6A, 4-5B, 4-6A, 5B5, 408 and 5C6. 
Data are graphed with LN(CPM/CK) on the X-
axis versus the exponential values of two-
fold dilutions of antigen on the Y-axis 
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Figure 22. Antigenic signatures of CPSMV II (the solid 
line) and CPSMV VII (the dotted line) using 
MAbs 5B, 6A, 4-5B, 4-6A, 5B5, 4D8 and 5C6. 
Data are graphed with LN(CPM/CK) on the X-
axis versus the exponential values of two-
fold dilutions of antigen on the Y-axis 
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Figure 23. Antigenic signatures of CPSMV II (the solid 
line) and CPSMV VIII (the dotted line) using 
MAbs 5B, 6A, 4-5B, 4-6A, 5B5, 408 and 5C6. 
Data are graphed with LN(CPM/CK) on the X-
axis versus the exponential values of two-
fold dilutions of antigen on the Y-axis 
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Figure 24. Antigenic signatures of CPSMV II (the solid 
line) and CPSMV IX (the dotted line) using 
MAbs 5B, 6A, 4-5B, 4-6A, 5B5, 408 and 5C6. 
Data are graphed with LN(CPM/CK) on the X-
axis versus the exponential values of two-
fold dilutions of antigen on the Y-axis 
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Figure 25. Antigenic signatures of CPSMV III (the solid 
line) and CPSMV IV (the dotted line) using 
MAbs 5B, 6A, 4-5B, 4-6A, 5B5, 408 and 5C6. 
Data are graphed with LN(CPM/CK) on the X-
axis versus the exponential values of two-
fold dilutions of antigen on the Y-axis 
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Figure 26. Antigenic signatures of CPSMV III (the solid 
line) and CPSMV V (the dotted line) using 
MAbs 5B, 6A, 4-5B, 4-6A, 5B5, 408 and 5C6. 
Data are graphed with LN{CPM/CK} on the X-
axis versus the exponential values of two-
fold dilutions of antigen on the Y-axis 
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Figure 27. Antigenic signatures of CPSMV III (the solid 
line) and CPSMV VI (the dotted line) using 
MAbs 5B, 6A, 4-5B, 4-6A, 5B5, 408 and 5C6. 
Data are graphed with LN{CPM/CK} on the X-
axis versus the exponential values of two-
fold dilutions of antigen on the Y-axis 
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Figure 28. Antigenic signatures of CPSMV III (the solid 
line) and CPSMV VII (the dotted line) using 
MAbs 5B, 6A, 4-5B, 4-6A, 5B5, 4D8 and 5C6. 
Data are graphed with LN(CPM/CK) on the X-
axis versus the exponential values of two-
fold dilutions of antigen on the Y-axis 
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Figure 29. Antigenic signatures of CPSMV III (the solid 
line) and CPSMV VIII (the dotted line) using 
MAbs 5B, 6A, 4-5B, 4-6A, 585, 4D8 and 5C6. 
Data are graphed with LN(CPM/CK} on the X-
axis versus the exponential values of two-
fold dilutions of antigen on the Y-axis 
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Figure 30. Antigenic signatures of CPSMV III (the solid 
line} and CPSMV IX (the dotted line) using 
MAbs 5B, 6A, 4-5B, 4-6A, 5B5, 4D8 and 5C6. 
Data are graphed with LN(CPM/CK) on the X-
axis versus the exponential values of two-
fold dilutions of antigen on the Y-axis 
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Figure 31. Antigenic signatures of CPSMV IV (the solid 
line) and CPSMV ' V (the dotted line) using 
MAbs 5B, 6A, 4-5B, 4-6A, 5B5, 408 and 5C6. 
Data are graphed with LN(CPM/CK) on the X-
axis versus the exponential values of two-
fold dilutions of antigen on the Y-axis 
CPSW rJ+V /58 CPSI.N rJtV /6A CPSUV W+V I 4-58 CPSW W+V/4-6F 
4 4 4 4 
3 3 3 3 
" " " " ~ } ~ } ll 2 ll 2 u u u 0 
" " " " l 1 11 l 1 l 1 a. a. ll a. u 0 0 0 v v v v 
3 0 3 D 3 0 3 0 
-1 -1 -1 -1 
-4 -4 ....z TTl 
0 1 l ~ 4 5 I 1 I I ~ II tt 0 1 l ~ 4 5 I 1 I I 10 II 12 0123451711101112 0123451711101112 
Dtlufun of hrtigen Dilution of hrtigen ~lution of hlligen Dilution of hi~ 
1--' 
CPSUV rJtV /585 CPSMV W+V I 408 CPSMV W+V /5C6 0 \D 
4 4 
l l 3 
" " " ll 2 y 2 y 2 
0 0 0 
" " " l 1 l 1 l 1 a. a. n_ 
u u 0 v v v 
3 0 3 D J D 
-1 -1 -1 
-l I I I I I I I I I I I I -2 -2 
o 1 2 J 4 5 1 1 a 1 10 11 12 0 I 2 3 4 5 I 7 a I ID II 12 D I 2 l 4 5 I 1 a I W 11 tt 
Dtlution of Mtigm Dilution of hrtigoo ljlution of hlligoo 
110 
Figure 32. Antigenic signatures of CPSMV IV (the solid 
line) and CPSMV VI (the dotted line) using 
MAbs 5B, 6A, 4-5B, 4-6A, 5B5, 408 and 5C6. 
Data are graphed wi th LN(CPM/CK) on the X-
axis versus the exponential values of two-
fold dilutions of antigen on the Y-axis 
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Figure 33. Antigenic signatures of CPSMV IV (the solid 
line) and CPSMV VII (the dotted line) using 
MAbs 5B, 6A, 4-5B, 4-6A, 5B5, 408 and 5C6. 
Data are graphed with LN(CPM/CK) on the X-
axis versus the exponential values of two-
fold dilutions of antigen on the Y-axis 
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Figure 34. Antigenic signatures of CPSMV IV (the solid 
line) and CPSMV VIII (the dotted line) using 
MAbs 5B, 6A, 4-5B, 4-6A, 5B5, 408 and 5C6. 
Data are graphed with LN{CPM/CK) on the X-
axis versus the exponential values of two-
fold dilutions of antigen on the Y- axis 
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Figure 35. Antigenic signatures of CPSMV IV (the solid 
line) and CPSMV IX (the dotted line) using 
MAbs 5B, 6A, 4-5B, 4-6A, 5B5, 408 and 5C6. 
Data are graphed with LN(CPM/CK} on the X-
axis versus the exponential values of two-
fold dilutions of antigen on the Y-axis 
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Figure 36. Antigenic signatures of CPSMV V (the solid 
line) and CPSMV VI (the dotted line) using 
MAbs 5B, 6A, 4-5B, 4-6A, 5B5, 408 and 5C6. 
Data are graphed with LN(CPM/CK) on the X-
axis versus the exponential values of two-
fold dilutions of antigen on the Y-axis 
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Figure 37. Antigenic signatures of CPSMV V (the solid 
line) and CPSMV VII (the dotted line) using 
MAbs 5B, 6A, 4-5B, 4-6A, 5B5, 4D8 and 5C6. 
Data are graphed with LN(CPM/CK) on the X-
axis versus the exponential values of two-
fold dilutions of antigen on the Y- axis 
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Figure 38. Antigenic signatures of CPSMV V (the solid 
line} and CPSMV VIII (the dotted line} using 
MAbs 5B, 6A, 4-SB, 4-6A, 5B5, 408 and 5C6. 
Data are graphed with LN(CPM/CK) on the X-
axis versus the exponential values of two-
fold dilutions of antigen on the Y-axis 
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Figure 39. Antigenic signatures of CPSMV V (the solid 
line) and CPSMV IX (the dotted line) using 
MAbs 5B, 6A, 4-5B, 4-6A, 5B5, 4D8 and 5C6. 
Data are graphed with LN(CPM/CK) on the X-
axis versus the exponential values of two-
fold dilutions of antigen on the Y-axis 
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Figure 40. Antigenic signatures of CPSMV VI (the solid 
line) and CPSMV VII (the dotted line) using 
MAbs 5B, 6A, 4-5B, 4-6A, 5B5, 408 and 5C6. 
Data are graphed with LN(CPM/CK) on the X-
axis versus the exponential values of two-
fold dilutions of antigen on the Y-axis 
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Figure 41. Antigenic signatures of CPSMV VI (the solid 
line) and CPSMV VIII (the dotted line) using 
MAbs 5B, 6A, 4-5B, 4-6A, 585, 408 and 5C6. 
Data are graphed with LN(CPM/CK) on the X-
axis versus the exponential values of two-
fold dilutions of antigen on the Y- axis 
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Figure 42. Antigenic signatures of CPSMV VI (the solid 
line) and CPSMV IX (the dotted line) using 
MAbs 5B, 6A, 4-5B, 4-6A, 5B5, 408 and 5C6. 
Data are graphed with LN(CPM/CK) on the X-
axis versus the exponential values of two-
fold dilutions of antigen on the Y-axis 
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Figure 43. Antigenic signatures of CPSMV VII (the solid 
line) and CPSMV VIII (the dotted line) using 
MAbs 5B, 6A, 4-5B, 4-6A, 5B5, 408 and 5C6. 
Data are graphed with LN(CPM/CK) on the X-
axis versus the exponential values of two-
fold dilutions of antigen on the Y-axis 
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Figure 44. Antigenic signatures of CPSMV VII (the solid 
line) and CPSMV IX (the dotted line) using 
MAbs 5B, 6A, 4-5B, 4-6A, 5B5, 408 and 5C6. 
Data are graphed with LN(CPM/CK) on the X-
axis versus the exponential values of two-
fold dilutions of antigen on the Y-axis 
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Figure 45. Antigenic signatures of CPSMV VIII (the solid 
line) and CPSMV IX (the dotted line) using 
MAbs 5B, 6A, 4-5B, 4-6A, 5B5, 408 and 5C6. 
Data are graphed with LN(CPM/CK) on the X-
axis versus the exponential values of two-
fold dilutions of antigen on the Y-axis 
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summarized in Table 3. The difference between two serotypes 
on one epitope was measured by visualizing the divergence of 
two curves. 
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Table 3. Comparison of serotypes of CPSMV by signature 
analysis, showing epitopic differences recognized 
by seven MAbs 
CPSMV I II III IV v VI VII VIII IX 
-----------------------------------------------------------
CPSMV I 5B - a + + + + + 
6A + + 
4-5B + + 
4-6F + + + + + + 
5B5 + + + + 
408 + + + + 
5C6 + + + + + + + + 
CPSMV II 5B + + + + + + + + 
6A + + + + + + + + 
4-5B + + + + + + + + 
4-6F + + + + + + + + 
5B5 + + + + 
408 + + + + 
5C6 + + + + + 
-----------------------------------------------------------
CPSMV III 5B + + + + + + 
6A + + + + + 
4-5B + + + 
4-6F + + + + + + + + 
5B5 + + + + + + 
408 + + + + + + + + 
5C6 + + + + + + + + 
-----------------------------------------------------------
CPSMV IV 5B + + + + + 
6A + + 
4-5B + 
4-6F + + + + + + + 
5B5 + + + + + 
408 + + + + + + + 
5C6 + + + + + + + 
---------------------------------------------------------------------------------------
a - or + indicates that there was no or some difference 
in the signature of the serotypes respectively. 
Table 3. 
CPSMV V 
CPSMV VI 
5B5 
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(continued) 
CPSMV I II III IV V VI VII VIII IX 
5B + + 
6A + 
4-5B + + + 
4-6F + + + 
5B5 + 
4D8 + 
5C6 + + 
5B + + + 
6A + + + 
4-5B + 
4-6F + + + 
+ + + + + 
408 + + + 
5C6 + + + 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ + 
+ + 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
-----------------------------------------------------------
CPSMV VII 5B + + + + + + 
6A + + + + 
4-5B + + + + 
4-6F + + + + + + + + 
5B5 + + + + + 
4D8 + + + + + + + + 
5C6 + + + + + + + 
-----------------------------------------------------------
CPSMV VIII 5B + + + + + + + 
6A + + + 
4-5B + + + + + 
4-6F + + + + + 
5B5 + + + 
4D8 + + + + 
5C6 + + + + + + 
-----------------------------------------------------------
CPSMV IX 5B + + + + + + + 
6A + + + + 
4-5B + + + 
4-6F + + + + + 
5B5 + + + + 
4D8 + + + + 
5C6 + + + + 
-----------------------------------------------------------
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DISCUSSION 
Cowpea (Vigna unguiculata Walp.) was an efficient host 
plant for the propagation of CPSMV. The yields of CPSMV were 
in the range of 50.7 mg-137 mg per kilogram of leaf tissue 
which agrees with the previous report of Lin et al. (1981). 
MAbs were produced with a modified version of the Van 
Deusen and Whetstone's protocol (1981). Since hybrid cells, 
particularly in the early stages of proliferation, may lose 
chromosomes rapidly, some positive hybridomas may cease to 
produce antibody. Thus cloning of hybridomas is required 
(Milstein, 1980). In our hands, the cloned cells remained 
stable. 
Limiting dilution and a calculation method were used for 
cloning. With the latter method, 30-40% of the wells had a 
single cell colony. With the limiting dilution approach, only 
10-20% of the wells had single cell colony. The best way to 
clone hybridomas is by using a flow cytometer because of its 
accuracy and rapidity. It can separate single cells into 
individual wells of a 96-well tissue culture plate and 
therefore saves the tedious work of diluting and checking 
wells under the light microscope. 
All the cell lines produced in this study were IgM-
producers. This may be the result of the immunization 
schedule and the use of Freund's complete adjuvant. However, 
all the cell lines against CPSMV I and II produced by Hill and 
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Kubanek independently were also IgM-producers. Therefore, it 
is still unknown if the viral antigen plays any role in these 
results. 
The purification of IgM has traditionally been more 
difficult than that of IgG. In this study, monoclonal IgM was 
purified from mouse ascitic fluid because ascitic fluid 
contains much more antibody than the culture supernatant 
(flask media) of hybridomas. As stated by Goding (1983), 
typical antibody concentrations in ascitic fluid range from 2 
to 20 mgjml while antibody concentrations in flask media range 
from 5 to 50 ugjml. our results are in good agreement with 
these observations. 
Monoclonal IgM was biotinylated in order to perform 
competition ELISAs. Previous reports indicated that IgG could 
be successfully labeled with 1:50 vjv and 5:1 moljmol ratio of 
biotin to IgG (Bayer et al., 1979). Since IgM is five times 
bigger than IgG, IgM was labeled with biotin in a 1:50 vjv and 
20:1 moljmol ratio of biotin to IgM in this study. 
Our competition ELISAs were designed to reveal whether 
the affinity or the concentration of a MAb has the most 
significant impact on its competition with a labeled antibody, 
and to provide information regarding the putative number of 
antigenic sites on the antigen for which the MAb competes. In 
simultaneous competition assays, the ability of an unlabeled 
antibody to compete with a labeled antibody is primarily 
affected by its concentration. The unlabeled antibody is 
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prepared in a series of dilutions and the concentration of 
labeled antibody remains constant. The two immunoreagents are 
added to the wells simultaneously and compete for antigenic 
sites on the antigen at the same time. Thus, at high 
concentrations of unlabeled antibody, more unlabeled antibody 
will bind to the antigen and competition will be greater. As 
the concentration of unlabeled antibody decreases, more 
labeled antibody binds to the antigen and competition 
declines. Affinity of the unlabeled antibody also plays an 
important role in competion in the simultaneous assays. If 
the unlabeled antibody and biotinylated antibody have the same 
affinity, competition will be approximately 50% because both 
antibodies have an equal chance of binding to epitopes on the 
antigen. 
Flask media were used as the source for the unlabeled 
MAbs. Although the IgM concentrations were not determined, 
they gave detectable absorbance readings in the antibody-
containing indirect ELISA tests. As Goding stated {1983), 
antibody levels in flask media are usually in the range of 5-
50 ugjml. All the three biotinylated antibodies (SB, 4-SB, 
5B5) had an optimum concentration of 5 ugjml for use in the 
competition assays. Therefore, it is possible that the 
undiluted unlabeled antibody had at least the same 
concentration as the labeled antibody. If no competition 
occurred when the flask medium containing the unlabeled 
antibody was undiluted, it was not because there was 
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insufficient antibody; rather, it was due to the low affinity 
of the unlabeled antibody for the epitope. 
In consecutive competition ELISA, however, the ability of 
unlabeled antibody to compete with a labeled antibody is 
primarily affected by affinity of the unlabeled antibody 
(Hosang, 1985). According to Berzofsky and Berkower (1984), 
the basic thermodynamic principles of antigen-antibody 
interactions are the same as those for any reversible 
bimolecular binding reaction. Its chemical equilibrium is 
K 
formulated as S + L == SL, where S = antibody binding sites, L 
= ligand (antigen) binding sites, SL = the complex of the two, 
and K = association constant (or affinity). In the 
consecutive assay, the unlabeled antibody is added to the well 
before the biotinylated antibody. If the unlabeled antibody 
has a high affinity, the equilibrium equation favors binding 
of the unlabeled antibody to the antigen. As a result, the 
binding of unlabeled antibody to binding sites will be favored 
over binding of biotinylated antibody applied later. 
Therefore, in this situation, the unlabeled antibody competes 
with the labeled antibody even at high dilutions, to a fairly 
significant degree. Conversely, if the unlabeled antibody is 
of low affinity, the equilibrium equation favours dissociation 
of antigen-antibody complex. More biotinylated antibody will 
replace the unlabeled antibody at the binding sites. 
Therefore, competition of the unlabeled antibody is lower. 
In analysis of competition curves for competitive 
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ability, both steepness and shape of the slopes are relevant 
as well as percent maximum absorbance values (Kubanek, 1987). 
In the simultaneous assay a steep slope suggests concentration 
of the unlabeled antibody does not have a large impact on its 
competition. If the slope increases gradually, the 
concentration influences competition. The consecutive assay 
is interpreted in a similar fashion. If the slope of the 
curve is steep, the data indicate that the antibody has a low 
affinity for the epitope and its affinity has little influence 
upon ability to compete. On the other hand, if the curve has 
a steep slope, the affinity of the unlabeled antibody has a 
significant impact upon its competition. 
The shape of the competition curve suggests the putative 
number of binding sites that the unlabeled antibody competes 
for on the antigen. The curve is generated as a regression 
line of the third order. Thus, if it is a monophasic curve, 
the unlabeled antibody probably competes for one site on the 
antigen. If the curve is diphasic, it indicates that the 
unlabeled antibody may compete with the labeled antibody for 
binding to two different antigenic sites. 
The percent maximum absorbance (PMA) values of both the 
simultaneous and consecutive assays (in a reasonable dilution 
range, from undiluted to 1:500) were also analyzed. If the 
PMA is lower in the consecutive than in the simultaneous 
assay, affinity is considered to have a greater impact than 
antibody concentration upon the ability of an antibody to 
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compete with the biotinylated antibody. If the PMA of the 
simultaneous assay is lower than the one in consecutive assay, 
the concentration is assumed to have more influence on the 
ability of the antibody to compete. 
By these criteria, the 23 MAbs utilized in this study 
were grouped into two major categories of those that did 
compete and those that did not. In the competition ELISA 
which employed CPSMV I as the antigen, MAbs G10, 4-5B, 3-11C, 
4-6F and 5B5 did not compete with biotinylated 5B because the 
PMA in both the simultaneous and consecutive assays were above 
75%. The remainder of the MAbs were assumed to compete. In 
the second set of competition assays with biotinylated 4-5B 
and CPSMV II, MAbs E2, 4-6F, 1-11G, 5B5 and 4D8 did not 
compete. In the third group of competition assays using CPSMV 
III, all the antibodies competed with biotinylated 5B5. 
Competition of the unlabeled antibodies with the biotinylated 
antibody was assessed by competition in either the 
simultaneous or the consecutive assay. 
Seven of the 23 MAbs were selected for use in signature 
analysis assays; therefore, only their characteristics are 
discussed below: 
5B 
MAb 5B was made against CPSMV I. It was selected for 
biotinylation because it had a very high capacity to bind to 
CPSMV I as determined by Kubanek (1987). The competition 
curves using CPSMV I as the antigen showed that MAb 5B 
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competes with biotinylated 5B. Evidently, concentration has a 
greater impact than affinity on competition, because the slope 
of the curve from the simultaneous assay was less steep than 
that from the consecutive assay. In addition, competition was 
lost at a dilution of 1:1000 in the simultaneous assay. No 
competition occured above a dilution of 1:50 in the 
simultaneous assay. The antibody only bound to one site on 
CPSMV I. 
The second set of competition curves demonstrated that 
the affinity of 5B was more significant in competition with 
biotinylated 4-5B than was concentration. It did not show 
competition, even when undiluted, in the simultaneous assay. 
It appeared to compete for two sites on CPSMV II, since it had 
a diphasic consecutive competition curve [Figure 2, 5B{2)]. 
MAb 5B competed for binding to two sites on CPSMV III 
with labeled 5B5. Although the steepness of two curves did 
not suggest much difference, concentration was more 
significant in competition against labeled 5B5, because its 
PMA was from 30% to 75% in the dilution range of undiluted to 
1:512. 
Therefore, MAb 5B was chosen for the signature analysis 
because it had a relatively high binding capacity, it was the 
biotinylated antibody in competition assays and it could also 
bind to two sites on CPSMV III. 
6A 
MAb 6A was made to CPSMV I. It did not compete well with 
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biotinylated 5B for sites on CPSMV I because the PMA in both 
assays was around 75% at all dilutions of flask medium. It 
appeared to bind to two sites on CPSMV I. 
The second set of competition curves suggested MAb 6A 
competed slightly with labeled MAb 4-5B. No competition was 
evident in the simultaneous assay and competition only 
occurred to a 1:16 dilution in the consecutive assay. It 
competed slightly for one site on CPSMV II. 
MAb 6A competed with biotinylated 5B5 for sites on CPSMV 
III. Its affinity and concentration seem to play an equal 
role in its competitive ability because the steepness of both 
curves was similar. The PMA was below 75% at a dilution of 
flask medium as high as 1:128 in both assays. It competed 
with labeled 5B5 for binding to two sites on CPSMV III. 
It was selected for signature analysis. Although the 
antibody was made to CPSMV I, it did not compete well with MAb 
5B, i.e., it may bind to a different epitope on CPSMV I. This 
site may be similar to a site on CPSMV III, since it competed 
well against 5B5 on CPSMV III. 
4-5B 
MAb 4-5B, a MAb made to CPSMV II, was selected to be 
biotinylated in the second set of competition ELISAs because 
it did not compete with labeled 5B for sites on CPSMV I, and 
it showed a higher capacity for binding to CPSMV II in an 
indirect ELISA. 
The second set of competition curves showed that affinity 
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and concentration of MAb 4-5B affected its competition more or 
less to the same degree. The slope of the curve in the 
simultaneous assay was slightly less steep than that of the 
consecutive curve. However, the competition was lost at a 
dilution of 1:128 in the consecutive assay and at 1:64 in the 
simultaneous assay. It bound to two sites on CPSMV II. 
In the third set of competition assays, affinity and 
concentration of MAb 4-5B again seemed to have similar effects 
on its competitive ability. The slope of the curve was 
similar and it lost competition at about the same dilution 
(1:64-1:128). It also competed for two sites on CPSMV III. 
MAb 4-5B was selected for signature analysis because it 
did not compete with MAb 5B for sites on CPSMV I. However, it 
competed very well with MAb 5B5 for sites on CPSMV III. 
Therefore, there may be a similar epitope on CPSMV II and III 
which was recognized by MAb 4-5B. 
4-6F 
MAb 4-6F, raised against CPSMV II, did not compete with 
both biotinylated 5B and 4-5B for antigenic sites on CPSMV I 
and II. 
It competed well with labeled 5B5 for sites on CPSMV III. 
The slope of the binding curves for both simultaneous and 
consecutive assays was similar; the PMA of the simultaneous 
binding curve suggested that concentration had a greater 
impact than affinity on its competition. It competed with MAb 
5B5 for binding to two sites on CPSMV III. 
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MAb 4-6F was chosen for signature analysis, because of 
its unique non-competitive nature with 5B and 4-5B. Since it 
was a MAb raised to CPSMV II, there may be an identical or 
similar epitope on both CPSMV II and III. 
5B5 
MAb 5B5 is a MAb made to CPSMV III. It was chosen for 
biotinylation for the third set of competition ELISAs and 
signature analysis, because it did not compete with both 
biotinylated MAbs 5B and 4-5B and it showed a very high 
binding ability to CPSMV III in an indirect ELISA. The 
competition curve against biotinylated MAb 5B5 showed that 
both concentration and affinity influenced its competition in 
both assays to a dilution of 1:512. It appeared to bind to 
one site on CPSMV III. 
408 
MAb 408 was made to CPSMV III. In the first competition 
assays, affinity influenced ability to compete with labeled 5B 
for sites on CPSMV I more than concentration. It did not 
compete beyond a 1:32 dilution of flask medium in the 
consecutive assay. The slope of the simultaneous curve was 
level with a constant PMA of about 70% at all dilutions. It 
competed with MAb 5B for one site on CPSMV I. 
It did not compete with MAb 4-5B for sites on CPSMV II. 
In competition with biotinylated 5B5 for sites on CPSMV 
III, the concentration of MAb 408 seemed to have a greater 
effect on ability to compete than affinity. The slope of the 
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two curves was very similar, but the PMA for the simultaneous 
assay was lower than that of consecutive assay. It bound to 
one site on CPSMV III. 
It was selected for signature analysis, because it did 
not compete with MAb 4-SB on CPSMV II and it competed with MAb 
5B on CPSMV I and with MAb 5B5 on CPSMV III. This suggested a 
similar epitope on CPSMV I and III. 
5C6 
MAb 5C6, an antibody raised to CPSMV III, did not compete 
well with MAb 5B for sites on CPSMV I because no competition 
occurred in the consecutive assay, and the PMA was 65% to over 
75% in the simultaneous assay. 
Competition with labeled MAb 4-5B for sites on CPSMV II 
did not occur beyond a 1:8 dilution of flask medium in the 
simultaneous assay, or beyond 1:32 in the consecutive assay. 
This indicated that affinity had a greater impact on 
competition with MAb 4-SB. It competed with MAb 4-SB for 
binding to two sites on CPSMV II. 
MAb 5C6 competed well with biotinylated MAb 5B5 for sites 
on CPSMV III. With a relatively level consecutive competition 
curve and the ability to compete even at a dilution of 1:512, 
the affinity of MAb 5C6 definitely had a greater impact on its 
competition. It bound to two sites on CPSMV III. 
It was chosen for signature analysis because unlike MAb 
408, it did compete with MAb 5B, but not with MAB 4-5B. The 
two antibodies 5C6 and 408 may reveal some subtle differences 
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between epitopes of CPSMV I, II, III. 
By employing a competition ELISA assay, Diaco et al. 
{1986) identified two epitopes on the coat protein of the P-
PAV strain of BYDV. He demonstrated that two MAbs totally 
inhibited binding of the biotinylated antibody while one MAb 
had virtually no effect on binding of the biotinylated 
antibody. Competition ELISA assays with a small panel (2 to 
3) of MAbs define only a limited number of epitopes on an 
antigen. They cannot demonstrate the subtle differences 
between a large number of epitopes. However, competition 
assays do provide a general idea concerning the relationships 
between epitopes. More importantly, they characterize MAbs by 
testing the impact of affinity and concentration on 
competition for epitopes on the antigen. 
The MAbs characterized in this study were chosen for use 
in signature analysis assays to demonstrate the relationships 
of epitopes on strains of CPSMV. MAbs 5B, 6A, 4-5B, 4-6F, 
5B5, 4D8 and 5C6 were selected on the basis of 1) ability to 
competitively bind to all three serotypes of CPSMV (5B, 6A, 
5C6), and 2) to not compete with the biotinylated antibody and 
therefore recognize distinct and separate antigenic 
determinants on CPSMV (4-5B, 4-6F, 5B5, 4D8). 
MAbs 6A, 4-6F, 4D8 and 5C6 were also biotinylated and 
used in a simple antibody competition assay together with 
biotinylated MAbs 5B, 4-5B and 5B5 to further characterize 
their competition (Table 2). The seven MAbs were shown to 
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compete with each other by 30 to 80% which agreed with results 
achieved in simultaneous and consecutive competition ELISAs in 
which four of the antibodies (i.e., 6A, 4-6F, 4D8 and 5C6) 
were not biotinylated. 
Serotypes I through IX of CPSMV were assayed by signature 
analysis, although there were no antibodies directly produced 
against serotypes IV to IX. The data showed that these 
heterologous antibodies could properly define epitopes on 
CPSMV IV-IX. our results reflected the interaction between 
antigenic epitopes and antibodies. When serotypes of CPSMV 
were compared, differences in the relative occurrence of each 
epitope as well as variations in affinity resulting from 
structural differences within the epitopes were reflected in 
the signatures. The signatures of each antibody with each 
antigen were generated by plotting the exponential values of 
two-fold dilution of antigen on the X-axis and LN(CPM/CK) on 
the Y-axis. The interaction of antigen at high concentrations 
with antibodies of relatively high affinity resulted in a 
relatively high signature curve. Since the affinity of an 
antibody to the epitope of an antige was constant, the 
signature curve would gradually drop as the concentration of 
the antigen decreased. When the signature curves of two 
serotypes against one MAb were superimposable, showing no 
divergence, these two serotypes were considered to have one 
quantitatively and qualitatively identical epitope. 
In our experiments, the antigen was prepared from freshly 
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infected leaves prior each experiment; therefore, the starting 
concentration of the antigens were probably different from one 
experiment to the other. The signature curves generated at 
different times would shift to the left or right if the 
starting antigen concentration was lower or higher, but the 
basic relationship of each curve to the other remained 
constant. Thus, a reproducible signature results (Van Deusen, 
1984). The fresh antigen dilutions used in this study varied 
from 1:2 to 1:2048 (two-fold dilutions). Extracts from 
uninoculated cowpeas at the same dilutions were used as a 
control. Results (author's unpublished results) suggested 
that, at higher concentrations (1:2 to 1:8), the cowpea plant 
sap may interfere with interactions between virus antigens and 
biotinylated antibodies. However, the CPMs resulting from the 
interaction between biotinylated antibodies and healthy cowpea 
sap from 1:16 to 1:2048 dilution were approximately the same 
as the negative control (with phosphate buffer) . Therefore, 
the interaction results between CPSMV serotypes and seven MAbs 
(sample CPM) were divided by uninoculated cowpea CPM at each 
equivalent dilution point, which were plotted on the Y-axis. 
Figures 10 to 45 showed the results of signature analysis 
assays with CPSMV I through IX and seven MAbs as well as a 
comparison of two serotypes against each antibody. Each curve 
was the result of the average of three independent analyses 
with three replicates each time. In signature analysis, the 
absolute antigen concentration of each virus sample was not 
155 
standardized. Therefore, a statistical (iterative least-
squares) technique (Ben-Porath et al., 1985) was used to align 
the curves generated with three CPSMV serotype (antigen) 
preparations. This allowed comparison of binding profiles and 
detection of both subtle and major antigenic differences. In 
this study, the antigenic signature differences were 
determined by visual assessment and scored "+" (major 
difference) and "-" (minute or no difference) (Table 3). 
However, statistical quantitation methods could be pursued to 
further demonstrate the differences of antigenic signatures 
among these nine serotypes of CPSMV. 
When all serotypes of CPSMV were compared, each had 
distinct binding profiles at multiple epitopes. Table 3 
illustrated the differences between serotypes of epitopes 
recognized by each of the seven MAbs. By immunodiffusion 
tests, Lin et al. (1981) showed that serotypes I to IV had a 
common antigenic determinant A. Serotypes I, III and IV 
shared an additional common determinant designated as B. 
Serotypes I and IV had a common epitope c. Each serotype also 
had a specific antigenic determinant D, E, F and G for 
serotypes I, II, III and IV, respectively. From Table 3, 
three common epitopes recognized by MAbs 5B, 6A and 4-5B were 
shared by CPSMV I, III and IV. But assumptions cannot be made 
to suggest that either epitope "5B", "GA" or "4-5B" was the 
determinant B identified with double diffusion tests. This is 
because the differences between serotypes recognized by 
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polyclonal antibodies reflect the differences of more than one 
epitope. In order to define the relationships between 
epitopes recognized by polyclonal antibodies and those by 
MAbs, double diffusion tests using side-by-side comparisons 
with both types of antibodies, could be utilized. 
By vertical and horizontal comparisons of data in Table 
3, the differences in reactivity of seven MAbs with nine CPSMV 
serotypes are easily identified. For example, Table 3 showed 
CPSMV II was very different from the other serotypes of CPSMV, 
which coincided the results obtained by Lin et al. (1984). In 
addition, Table 3 showed that CPSMV VIII was slightly 
different from CPSMV IX on only epitopes "5B" and "4-5B". 
Since each labeled MAb and 125I-labeled avidin were used 
at identical protein concentrations, the affinity differences 
between virus serotypes could be measured. In Figure 10, the 
frequency of epitope 6A was higher than epitope 4-5B for CPSMV 
I. In Figure 10, the relative affinity of antibody 5B for its 
epitope on CPSMV III was higher than that on CPSMV I. 
In this study, all antibodies were IgM. Biotin and 
avidin system instead of direct 125I-labeling had to be used 
in order to preserve the reactivity of the antibodies. This 
could be the reason that the differences among nine serotypes 
of CPSMV are not very striking. However, signature analysis 
has been proven to be able to differentiate nine serotypes of 
CPSMV. However, only seven MAbs were used in this study. In 
order to further elucidate the differences of CPSMV serotypes, 
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more MAbs should be included. 
Signature analysis, as a relatively new technique, has 
not, until this study, been applied to plant virology. Its 
ability to define the subtle antigenic differences among 
animal viruses (Wands et al., 1984; Monath et al., 1986) and 
plant viruses (this study) has been well demonstrated. This 
technique will be most valuable in establishing signatures 
common to several isolates so that new strains (serotypes) may 
be compared to the prevalent strain (serotype) (Monath, 1986}. 
This may allow comparison between strains (serotypes) derived 
from different geographic regions and permit classification of 
variant strains. It may be possible to trace the genetic 
evolution and antigen drift of plant viruses. This is 
important to plant virologists since we have not been able to 
label viruses as do the plant mycologists and bacteriologists. 
In addition, antigenic drift would possibly indicate that new 
serotypes of virus may have developed and they might be able 
to overcome resistant hosts. This could have implications for 
the breeding of resistant plants which is by far the most 
feasible way to control plant viral disease. 
Agrawal, H. 
isolates. 
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Figure Al. Competition profiles of MAb E2 with biotin-
labeled MAbs in simultaneous (•--•) and 
consecutive (~--•) competition ELISAs. MAbs 
were made to CPSMV. E2(1): competition between 
E2 and labeled 5B using CPSMV I. E2(2): 
competition between E2 and labeled 4-5B using 
CPSMV II. E2(3): competition between E2 and 
labeled 5B5 using CPSMV III. Percent maximum 
absorbance is equal to the average absorbance of 
the sample divided by the average absorbance of 
the positive control 
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Figure A2. Competition profiles of MAb Fl with biotin-
labeled MAbs in simultaneous (•--•) and 
consecutive (•--•) competition ELISAs. MAbs 
were made to CPSMV. Fl(l): competition between 
Fl and labeled 5B using CPSMV I. Fl(2): 
competition between Fl and labeled 4-5B using 
CPSMV II. Fl(3): competition between Fl and 
labeled 5B5 using CPSMV III. Percent maximum 
absorbance is equal to the average absorbance of 
the sample divided by the average absorbance of 
the positive control 
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Figure A3. Competition profiles of MAb GlO with biotin-
labeled MAbs in simultaneous (•--•) and 
consecutive (4--4) competition ELISAs. MAbs 
were made to CPSMV. GlO(l): competition between 
GlO and labeled 5B using CPSMV I. Gl0(2): 
competition between GlO and labeled 4-5B using 
CPSMV II. Gl0(3): competition between GlO and 
labeled 5B5 using CPSMV III. Percent maximum 
absorbance is equal to the average absorbance of 
the sample divided by the average absorbance of 
the positive control 
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Figure A4. Competition profiles of MAb H6 with biotin-
labeled MAbs in simultaneous (•---•) and 
consecutive (•---•) competition ELISAs. MAbs 
were made to CPSMV. H6(1): competition between 
H6 and labeled 5B using CPSMV I. H6(2): 
competition between H6 and labeled 4-SB using 
CPSMV II. H6(3): competition between H6 and 
labeled 5B5 using CPSMV III. Percent maximum 
absorbance is equal to the average absorbance of 
the sample divided by the average absorbance of 
the positive control 
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Figure A5. Competition profiles of MAb 2-7A with biotin-
labeled MAbs in simultaneous (•--•) and 
consecutive (•--~) competition ELISAs. MAbs 
were made to CPSMV. 2-7A(l): competition 
between 2-7A and labeled 5B using CPSMV I. 
2-7A(2): competition between 2-7A and labeled 4-
5B using CPSMV II. 2-7A(3): competition between 
2-7A and labeled 5B5 using CPSMV III. Percent 
maximum absorbance is equal to the average 
absorbance of the sample divided by the average 
absorbance of the positive control 
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Figure A6. Competition profiles of MAb 2-llA with biotin-
labeled MAbs in simultaneous (•--•) and 
consecutive (~--~) competition ELISAs. MAbs 
were made to CPSMV. 2-llA(l): competition 
between 2-llA and labeled 5B using CPSMV I. 
2-11A(2): competition between 2-llA and labeled 
4-5B using CPSMV II. 2-11A(3): competition 
between 2-llA and labeled 5B5 using CPSMV III. 
Percent maximum absorbance is equal to the 
average absorbance of the sample divided by the 
average absorbance of the positive control 
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Figure A7. Competition profiles of MAb 3-9C with biotin-
labeled MAbs in simultaneous (•--•) and 
consecutive (•--•) competition ELISAs. MAbs 
were made to CPSMV. 3-9C(l): competition 
between 3-9C and labeled 5B using CPSMV I. 
3-9C(2): competition between 3-9C and labeled 
4-5B using CPSMV II. 3-9C(3): competition 
between 3-9C and labeled 5B5 using CPSMV III. 
Percent maximum absorbance is equal to the 
average absorbance of the sample divided by the 
average absorbance of the positive control 
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Figure A8. Competition profiles of MAb 3-llC with biotin-
labeled MAbs in simultaneous (•--•) and 
consecutive (~--~) competition ELISAs. MAbs 
were made to CPSMV. 3-llC(l): competition 
between 3-llC and labeled 5B using CPSMV I. 
3-11C(2): competition between 3-llC and labeled 
4-5B using CPSMV II. 3-11C(3): competition 
between 3-llC and labeled 5B5 using CPSMV III. 
Percent maximum absorbance is equal to the 
average absorbance of the sample divided by the 
average absorbance of the positive control 
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Figure A9. Competition profiles of MAb 2-lF with biotin-
labeled MAbs in simultaneous (•---•) and 
consecutive (•--A) competition ELISAs. MAbs 
were made to CPSMV. 2-lF(l): competition 
between 2-lF and labeled 5B using CPSMV I. 
2-1F(2): competition between 2-lF and labeled 
4-5B using CPSMV II. 2-1F(3): competition 
between 2-lF and labeled 5B5 using CPSMV III. 
Percent maximum absorbance is equal to the 
average absorbance of the sample divided by the 
average absorbance of the positive control 
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Figure AlO. Competition profiles of MAb 4-5F with biotin-
labeled MAbs in simultaneous (•---•) and 
consecutive (•---•) competition ELISAs. MAbs 
were made to CPSMV. 4-5F(l): competition 
between 4-5F and labeled 5B using CPSMV I. 
4-5F(2): competition between 4-5F and labeled 
4-5B using CPSMV II. 4-5F(3): competition 
between 4-5F and labeled 5B5 using CPSMV III. 
Percent maximum absorbance is equal to the 
average absorbance of the sample divided by the 
average absorbance of the positive control 
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Figure All. Competition profiles of MAb l-9G with biotin-
labeled MAbs in simultaneous (•--•) and 
consecutive (~--~) competition ELISAs. MAbs 
were made to CPSMV. l-9G(l}: competition 
between l-9G and labeled 5B using CPSMV I. 
l-9G(2}: competition between l-9G and labeled 
4-5B using CPSMV II. l-9G(3}: competition 
between l-9G and labeled 5B5 using CPSMV III. 
Percent maximum absorbance is equal to the 
average absorbance of the sample divided by the 
average absorbance of the positive control 
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Figure A12. Competition profiles of MAb 1-11G with biotin-
labeled MAbs in simultaneous (•--•) and 
consecutive (A--•) competition ELISAs. MAbs 
were made to CPSMV. 1-11G(1): competition 
between 1-11G and labeled 5B using CPSMV I. 
1-11G(2): competition between 1-11G and labeled 
4-5B using CPSMV II. 1-11G(3): competition 
between 1-11G and labeled 5B5 using CPSMV III. 
Percent maximum absorbance is equal to the 
average absorbance of the sample divided by the 
average absorbance of the positive control 
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Figure Al3. Competition profiles of MAb 2-llG with biotin-
labeled MAbs in simultaneous (•--•) and 
consecutive (•--~) competition ELISAs. MAbs 
were made to CPSMV. 2-llG(l): competition 
between 2-llG and labeled 5B using CPSMV I. 
2-11G(2): competition between 2-llG and labeled 
4-5B using CPSMV II. 2-11G(3): competition 
between 2-llG and labeled 5B5 using CPSMV III. 
Percent maximum absorbance is equal to the 
average absorbance of the sample divided by the 
average absorbance of the positive control 
190 
140 • 
• 120 u c 
ICI 100 -e 
0 • 80 ~ 
E 60 :I 
E 
')( 
ICI 40 
2 
M 20 2-11G (1) 
0 
0 1 2 3 4 5 6 7 8 9 10 11 12 
Antibody Dilution (2-x+ 1) 
140 
• 120 u • c 
ICI 100 -e 
0 • 80 ~ 
E 60 :I 
E 
')( 
40 ICI 
2 • 20 2-11G (2) 
0 
0 1 2 3 4 5 6 7 8 9 10 11 12 
Antibody Dilution (2-x+ 1) 
140 
3 
120 
c 
ICI 100 -e 
0 • 80 ~ 
E 60 :I 
E 
')( 
40 ICI 
2 • 20 2-11G (3) 
0 
Antibody Dilution (2-x+ 1) 
191 
Figure A14. Competition profiles of MAb 2Hl0 with biotin-
labeled MAbs in simultaneous (•--•) and 
consecutive (A--•) competition ELISAs. MAbs 
were made to CPSMV. 2Hl0(1): competition 
between 2Hl0 and labeled 5B using CPSMV I. 
2Hl0(2): competition between 2Hl0 and labeled 
4-5B using CPSMV II. 2Hl0(3): competition 
between 2Hl0 and labeled 5B5 using CPSMV III. 
Percent maximum absorbance is equal to the 
average absorbance of the sample divided by the 
average absorbance of the positive control 
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Figure A15. Competition profiles of MAb 3E7 with biotin-
labeled MAbs in simultaneous (•--•) and 
consecutive (A--•) competition ELISAs. MAbs 
were made to CPSMV. 3E7(1): competition 
between 3E7 and labeled 5B using CPSMV I. 
3E7(2): competition between 3E7 and labeled 
4-5B using CPSMV II. 3E7(3): competition 
between 3E7 and labeled 5B5 using CPSMV III. 
Percent maximum absorbance is equal to the 
average absorbance of the sample divided by the 
average absorbance of the positive control 
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Figure A16. Competition profiles of MAb 6B3 with biotin-
labeled MAbs in simultaneous (•--•) and 
consecutive (A--•) competition ELISAs. MAbs 
were made to CPSMV. 6B3(1): competition 
between 6B3 and labeled 5B using CPSMV I. 
6B3(2): competition between 6B3 and labeled 
4-5B using CPSMV II. 6B3(3): competition 
between 6B3 and labeled 5B5 using CPSMV III. 
Percent maximum absorbance is equal to the 
average absorbance of the sample divided by the 
average absorbance of the positive control 
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Figure Bl. Antigenic signatures of CPSMV I determined by 
seven MAbs with three independent virus 
preparations. Three sets of data ( -- , , 
-- ) are graphed with LN(CPM/CK) on the Y-axis 
versus the exponential values of two-fold 
dilutions of antigen on the X-axis 
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Figure B2. Antigenic signatures of CPSMV II determined by 
seven MAbs with three independent virus 
preparations. Three sets of data ( -- , , 
-- ) are graphed with LN(CPM/CK) on the Y-axis 
versus the exponential values of two-fold 
dilutions of antigen on the X-axis 
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Figure B3. Antigenic signatures of CPSMV III determined by 
seven MAbs with three independent virus 
preparations. Three sets of data ( -- , , 
-- ) are graphed with LN(CPM/CK) on the Y-axis 
versus the exponential values of two-fold 
dilutions of antigen on the X-axis 
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Figure B4. Antigenic signatures of CPSMV IV determined by 
seven MAbs with three independent virus 
preparations. Three sets of data ( -- , , 
-- ) are graphed with LN(CPM/CK) on the Y-axis 
versus the exponential values of two-fold 
dilutions of antigen on the X-axis 
CPSWW I 58 CPSMVW I 6A CPSI.N N I 4-58 CPSMV N I 4-6F 
4 4 4 
l l l 
" "' " " l( 2 l( 2 y 2 y 2 
0 0 I 0 0 
' ' ' ' l 1 & l 1 l 1 ll L II. II. 11. 
0 0 0 0 v v v v 
3 0 3 0 3 0 3 0 
-1 -1 -1 I 1 I I -1 
-1 -1 -2 -2 
0123451711101112 0 1 2 3 4 5 I 7 8 I 10 11 12 0123451781101112 0 I 2 3 ~ 5 I 7 I I 10 11 12 
Dtlulion of ,Antigen Dilution of hrtigen Dilution of httigeo Dilution of ht~eo 
N 
0 
CPSW N I 5B5 CPSIN N I 4D8 CPSMV N I 5C6 U1 
4 
3 3 3 
"' r\ " y 2 l( 2 y 2 
0 0 & 0 
' ' ' l 1 l I l 1 L II. n. 
0 0 0 v v v 
3 0 3 0 J 0 
-1 • -1 -1 I I I 
I I I • 
-z I I -2 -2 
0 1 2 l 4 5 I 7 I I 10 11 12 0 1 2 l 4 5 I 1 8 I 10 11 12 o 1 2 l 4 5 a 1 a t 10 11 u 
D~ution of httigen Dilution of Mtigeo Dilution of httigeo 
206 
Figure B5. Antigenic signatures of CPSMV V determined by 
seven MAbs with three independent virus 
preparations. Three sets of data ( -- , , 
-- ) are graphed with LN(CPM/CK) on the Y-axis 
versus the exponential values of two-fold 
dilutions of antigen on the X-axis 
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Figure B6. Antigenic signatures of CPSMV VI determined by 
seven MAbs with three independent virus 
preparations. Three sets of data ( -- , , 
-- ) are graphed with LN(CPM/CK) on the Y-axis 
versus the exponential values of two-fold 
dilutions of antigen on the X-axis 
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Figure B7. Antigenic signatures of CPSMV VII determined by 
seven MAbs with three independent virus 
preparations. Three sets of data ( -- , , 
-- ) are graphed with LN(CPM/CK) on the Y-axis 
versus the exponential values of two-fold 
dilutions of antigen on the X-axis 
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Figure B8. Antigenic signatures of CPSMV VIII determined by 
seven MAbs with three independent virus 
preparations. Three sets of data ( -- , , 
-- ) are graphed with LN(CPM/CK) on the Y-axis 
versus the exponential values of two-fold 
dilutions of antigen on the X-axis 
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Figure B9. Antigenic signatures of CPSMV IX determined by 
seven MAbs with three independent virus 
preparations. Three sets of data ( -- 1 1 
-- ) are graphed with LN(CPM/CK) on the Y-axis 
versus the exponential values of two-fold 
dilutions of antigen on the X-axis 
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